KR20170136930A - Composition for improving skin condition comprising herb extracts mixture - Google Patents
Composition for improving skin condition comprising herb extracts mixture Download PDFInfo
- Publication number
- KR20170136930A KR20170136930A KR1020160069102A KR20160069102A KR20170136930A KR 20170136930 A KR20170136930 A KR 20170136930A KR 1020160069102 A KR1020160069102 A KR 1020160069102A KR 20160069102 A KR20160069102 A KR 20160069102A KR 20170136930 A KR20170136930 A KR 20170136930A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- extracts
- skin
- ginseng
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 345
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 230000000694 effects Effects 0.000 claims abstract description 84
- 230000037303 wrinkles Effects 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 239000012676 herbal extract Substances 0.000 claims abstract description 7
- 210000003491 skin Anatomy 0.000 claims description 67
- 239000002904 solvent Substances 0.000 claims description 47
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 235000008708 Morus alba Nutrition 0.000 claims description 25
- 240000000249 Morus alba Species 0.000 claims description 25
- 239000002537 cosmetic Substances 0.000 claims description 23
- 210000004207 dermis Anatomy 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 22
- 235000020710 ginseng extract Nutrition 0.000 claims description 21
- 244000111489 Gardenia augusta Species 0.000 claims description 20
- 235000020708 ginger extract Nutrition 0.000 claims description 19
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 17
- 229940002508 ginger extract Drugs 0.000 claims description 17
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 16
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 16
- 230000002087 whitening effect Effects 0.000 claims description 16
- 240000004371 Panax ginseng Species 0.000 claims description 15
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 13
- 235000008434 ginseng Nutrition 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 11
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 9
- 230000007760 free radical scavenging Effects 0.000 claims description 9
- 229940010454 licorice Drugs 0.000 claims description 9
- 241000245665 Taraxacum Species 0.000 claims description 8
- 230000003064 anti-oxidating effect Effects 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 235000011511 Diospyros Nutrition 0.000 claims description 4
- 244000236655 Diospyros kaki Species 0.000 claims description 4
- 235000002789 Panax ginseng Nutrition 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 235000011201 Ginkgo Nutrition 0.000 claims 3
- 244000194101 Ginkgo biloba Species 0.000 claims 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims 3
- 240000006054 Agastache cana Species 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 abstract description 12
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 230000035755 proliferation Effects 0.000 abstract description 7
- 230000037394 skin elasticity Effects 0.000 abstract description 5
- 241000533367 Cnidium officinale Species 0.000 abstract description 3
- 241000784897 Fritillaria verticillata Species 0.000 abstract description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001603 reducing effect Effects 0.000 abstract description 3
- 210000000582 semen Anatomy 0.000 abstract description 3
- 241000202755 Areca Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 37
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 34
- 238000000605 extraction Methods 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 27
- 241000196324 Embryophyta Species 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 21
- 238000001816 cooling Methods 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000011148 porous material Substances 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 17
- 239000006210 lotion Substances 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 240000001972 Gardenia jasminoides Species 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 12
- 240000008397 Ganoderma lucidum Species 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 241000234314 Zingiber Species 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- -1 superoxide radicals Chemical class 0.000 description 12
- 230000000699 topical effect Effects 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 206010040880 Skin irritation Diseases 0.000 description 10
- 235000006886 Zingiber officinale Nutrition 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000001882 diuretic effect Effects 0.000 description 10
- 235000008397 ginger Nutrition 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 10
- 230000036556 skin irritation Effects 0.000 description 10
- 231100000475 skin irritation Toxicity 0.000 description 10
- 102000016942 Elastin Human genes 0.000 description 9
- 108010014258 Elastin Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 229920002549 elastin Polymers 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 8
- 241000208838 Asteraceae Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 7
- 235000017491 Bambusa tulda Nutrition 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 description 7
- 241001633628 Lycoris Species 0.000 description 7
- 244000082204 Phyllostachys viridis Species 0.000 description 7
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 239000011425 bamboo Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000018958 Gardenia augusta Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 241000207844 Scrophulariaceae Species 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 229940069445 licorice extract Drugs 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 229940027779 persimmon extract Drugs 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 241001133760 Acoelorraphe Species 0.000 description 4
- 244000080767 Areca catechu Species 0.000 description 4
- 241000132011 Atractylodes lancea Species 0.000 description 4
- 240000005250 Chrysanthemum indicum Species 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 241000721662 Juniperus Species 0.000 description 4
- 241000207923 Lamiaceae Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 241000209504 Poaceae Species 0.000 description 4
- 241000405911 Rehmannia glutinosa Species 0.000 description 4
- 241001093501 Rutaceae Species 0.000 description 4
- 235000007303 Thymus vulgaris Nutrition 0.000 description 4
- 240000002657 Thymus vulgaris Species 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
- 235000019209 bilberry extract Nutrition 0.000 description 4
- 229940102480 bilberry extract Drugs 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001585 thymus vulgaris Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000005292 vacuum distillation Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- 241000208422 Rhododendron Species 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 230000003217 anti-cancerogenic effect Effects 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000008738 huangbai Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 206010001986 Amoebic dysentery Diseases 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 235000006226 Areca catechu Nutrition 0.000 description 2
- 241000233788 Arecaceae Species 0.000 description 2
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 2
- 241000984231 Atractylodes chinensis Species 0.000 description 2
- 241000092665 Atractylodes macrocephala Species 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 241000555678 Citrus unshiu Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 241000218202 Coptis Species 0.000 description 2
- 241000037740 Coptis chinensis Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 241000218203 Coptis japonica Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000234646 Cyperaceae Species 0.000 description 2
- 241000234653 Cyperus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 241000169101 Hyacinthaceae Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000244365 Ligusticum sinense Species 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- 208000032923 Lobar pneumonia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 241000123069 Ocyurus chrysurus Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000972672 Phellodendron Species 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- 235000001550 Phyllostachys bambusoides Nutrition 0.000 description 2
- 240000007880 Phyllostachys bambusoides Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000219492 Quercus Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 241001107098 Rubiaceae Species 0.000 description 2
- 244000272264 Saussurea lappa Species 0.000 description 2
- 235000006784 Saussurea lappa Nutrition 0.000 description 2
- 206010039587 Scarlet Fever Diseases 0.000 description 2
- 241001551940 Scrophularia buergeriana Species 0.000 description 2
- 241001121987 Scrophularia ningpoensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 2
- 244000250129 Trigonella foenum graecum Species 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 201000004484 acute conjunctivitis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000020535 bottled fortified water Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940007061 capsicum extract Drugs 0.000 description 2
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 235000015897 energy drink Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000000295 fuel oil Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229960000869 magnesium oxide Drugs 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000001720 vestibular Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008434 yi-zhi Substances 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000120541 Rhizophora Species 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 피부 적용시 안전하고, 피부 개선 효과가 우수한 복합 생약 추출물을 유효성분으로 포함하는 조성물에 관한 것이다. The present invention relates to a composition containing as an active ingredient a complex herbal extract which is safe when applied to skin and has excellent skin improving effect.
피부는 외부 환경으로부터 인체를 보호하고, 내부의 수분 및 유용 성분이 밖으로 유출되는 것을 막아주는 장벽 기능, 체온조절 기능, 배설 기능 등 다양한 생리적 기능을 담당하고 있는 중요한 기관이다. 그러나, 다음과 같은 이유 등에 의해 피부 세포의 활성이 저하되고 피부 상태가 악화되는 현상이 일어날 수 있다.The skin is an important body that is responsible for various physiological functions such as barrier function, body temperature control function, excretion function, which protects the human body from the external environment and prevents the internal moisture and useful components from flowing out. However, due to the following reasons, the activity of skin cells may deteriorate and the skin condition may deteriorate.
피부의 진피층에 존재하는 콜라겐과 엘라스틴은 피부의 기계적 견고성, 결합조직의 저항력, 조직의 결합력 유지, 및 세포접착의 지탱 등의 기능을 수행하여 피부의 구성성분에 많은 영향을 미친다. 이러한 콜라겐은 스트레스, 고령화 또는 자외선 조사에 의한 광 노화에 의하여 감소되며, 한편, 엘라스틴은 자외선에 노출된 후 활성이 증가된 분해효소 엘라스타제에 의해 3차원 구조가 뒤틀려진다고 알려져있다. 이에 따라 피부 조직이 느슨해지고 탄력을 잃게 된다. Collagen and elastin present in the dermis of the skin perform functions such as mechanical rigidity of the skin, resistance of the connective tissue, maintenance of the cohesion of the tissue, and support of the cell adhesion, and have a great influence on the constituents of the skin. It is known that such collagen is reduced by photoaging due to stress, aging, or ultraviolet irradiation, while elastin is known to be distorted in its three-dimensional structure by the degrading enzyme elastase, which is activated after exposure to ultraviolet light. As a result, the skin tissue is loosened and the elasticity is lost.
표피의 세포 기능이 저하됨으로써 신진대사 작용이 원활하지 못하게 되어, 각질 탈락이 잘 일어나지 않아 각질이 과하게 축적된 상태에서 자외선을 받으면 탄력이 저하되어 주름 발생을 초래하게 된다. 또는 표피에 피지막이 형성되지 않을 경우 수분과 피지 분비가 감소하고 피부가 건조해지면서 주름이 형성되기도 한다. When the cell function of the epidermis is lowered, the metabolism is not smooth and the exfoliation does not occur well, and when the ultraviolet rays are received in a state where the keratin is overly accumulated, the elasticity is lowered and wrinkles are generated. If the skin is not formed on the epidermis, moisture and sebum secretion are reduced, and the skin becomes dry and wrinkles are formed.
피부가 자외선을 받으면 피부를 보호하기 위해 멜라닌을 합성한다. 합성된 멜라닌은 멜라노좀을 통해 피부의 각질세포로 옮겨진다. 이 각질 세포는 28일을 주기로 턴-오버(turn over) 현상이 일어난다. 따라서 생성된 멜라닌은 각질세포에 의해 28일을 주기로 소실되는 것이 일반적이나, 스트레스, 피부 노화 등에 의해 피부 세포 주기가 잘 조절되지 않게 되면 각질세포가 제시기에 탈락하지 않아 기미, 주근깨, 검버섯 등의 색소 침착이 일어나게 된다. When the skin receives ultraviolet rays, melanin is synthesized to protect the skin. The synthesized melanin is transferred to the keratinocytes of the skin through the melanoma. This keratinocyte turns over over a period of 28 days. Therefore, the melanin produced is generally lost by the keratinocyte periodically for 28 days. However, when the skin cell cycle is not properly controlled by the stress, skin aging, etc., keratinocytes do not fall out in the presentation period and the pigment such as spots, freckles, Calm occurs.
피부에서는 피지, 땀 성분 및 화장품 성분들이 피부 상재균에 의해 독성이 강한 물질로 분해되어 피부에 자극을 일으키고 염증을 유발시킬 수 있다. 또한 자외선으로 인한 자극으로 피부에 염증 매개 물질인 일산화질소(NO)의 생성을 증가시켜 피부 트러블이 유발될 수 있다. 일산화질소의 생성은 대부분 iNOS에 의한 것인데, iNOS는 LPS, 사이토카인 같은 자극에 의해 급격하게 유도되어 과량의 NO를 생성하는 것으로 알려져있다.In the skin, sebum, sweat and cosmetic ingredients are decomposed into substances that are toxic to the skin by the fungus, which can cause skin irritation and inflammation. In addition, skin irritation caused by ultraviolet rays increases the production of nitrogen monoxide (NO), which is an inflammation mediator, to cause skin troubles. The production of nitrogen monoxide is mostly caused by iNOS, and it is known that iNOS is rapidly induced by stimulation such as LPS and cytokine to produce excessive NO.
유해산소(toxic oxygen species)라고도 하는 활성산소종(reactive oxygen species, ROS)은 호흡 등과 같은 생리작용에 의해 세포에서 생성되는 독성물질로 끊임없이 생산되고 소멸하며, 정상적인 상태에서는 3-5% 정도로 존재한다. 이런 활성산소종은 수퍼옥시드 라디칼(Superoxide radical, O2-), 하이드록시라디칼 (hydroxyl radical, HO+)과 같은 자유라디칼(free radical: 화학적으로 최외각 전자궤도에 쌍을 이루고 있지 않은 원자나 분자로 매우 불안정하여 높은 반응성을 가지는 형태)로 존재하거나 혹은 과산화수소(hydorgen peroxide, H2O2)나 일중항산소(Singlet radical)와 같이 쌍을 이룬 전자를 가진 화합물의 형태로 존재한다. 활성산소종은 생리계 내에서 세균을 살균하는 생체 방어 작용을 하는 장점도 있지만, 일반적으로 생체 내에서 산화를 일으켜 질병의 원인이 되는 유해한 작용을 한다. 이러한 활성산소종은 생물분자를 공격하여 세포나 조직에 피해를 주며, 노화나 각종 성인병 질환에 관여하는 여러 종류의 질병을 야기한다는 보고가 있다. A reactive oxygen species (ROS), also known as a toxic oxygen species, is a cell-generated toxic substance produced by physiological actions such as respiration and is constantly produced and extinguished, with 3-5% in normal conditions . These reactive oxygen species are free radicals such as superoxide radicals (O2-) and hydroxyl radicals (HO +), which are chemically bound to atoms or molecules that are not paired with the outermost electron orbits Highly unstable and highly reactive) or in the form of compounds with paired electrons such as hydrogen peroxide (H 2 O 2 ) or singlet radicals. Active oxygen species have the advantage of biologically protecting bacteria in the physiological system, but generally cause oxidation in vivo, causing harmful effects that cause disease. It has been reported that these reactive oxygen species attack biological molecules and damage cells and tissues and cause various diseases related to aging and various diseases.
상술한 여러 요인들에 의한 피부 노화를 억제하고, 미백, 주름, 탄력 또는 트러블을 개선하고, 항산화 효과가 있는 물질을 개발하고자 하는 연구가 계속되어 왔다. Research has been continued to suppress the skin aging caused by various factors as described above, to improve whitening, wrinkles, elasticity or trouble, and to develop a substance having an antioxidative effect.
상술한 효과가 있는 물질은 자연계에 널리 분포되어 있는데, 주로 식물로부터 유래된 물질을 사용해 식품, 화장품, 의약품 등의 원료로서 사용해 왔다. 그러나, 이 같은 자연계에서 유래된 물질은 효과가 크지 않아 유의미한 효과를 얻기 위해서는 다량으로 사용해야 하고, 이로 인한 독성 및 가격 상승 문제가 대두되었다. Materials having the above-mentioned effects are widely distributed in the natural world, and they have been mainly used as raw materials for foods, cosmetics, medicines and the like using materials derived from plants. However, the substances derived from such natural substances are not effective enough to be used in large quantities in order to obtain a meaningful effect, resulting in toxicity and price increase.
이러한 천연 물질의 문제점을 해결하기 위해, 화학적으로 합성된 물질의 개발이 이어졌다. 이들은 천연 물질에 비해 소량 사용으로도 월등히 우수한 효과를 발휘한다는 장점이 있으나, 반면 인체에 크고 작은 부작용을 유발시킬 수 있다는 치명적인 문제점이 있어 사용이 제한된다. In order to solve the problems of such natural materials, the development of chemically synthesized materials has continued. Although they have a merit that they exert a superior effect even when used in a small amount compared to a natural substance, their use is limited due to a fatal problem that can cause large and small side effects to the human body.
이에, 피부 개선에 우수한 효과를 발휘하면서도 천연물로부터 유래되어 안정성이 확보되는 물질의 개발이 절실한 실정이다. Accordingly, it is inevitable to develop a substance derived from a natural product and having stability, while exhibiting an excellent effect on skin improvement.
본 발명이 해결하고자 하는 과제는 피부 개선, 특히 미백, 주름, 탄력, 트러블 개선, 항산화에 우수한 효과를 발휘하면서도 천연물로부터 유래되어 안정성이 확보되는 복합 생약 추출물을 제공하는데 있다. A problem to be solved by the present invention is to provide a complex herbal medicine extract which is derived from natural materials and has stability, while exhibiting excellent effects on skin, in particular whitening, wrinkle, elasticity, trouble improvement and antioxidation.
상술한 과제를 해결하기 위하여, 본 발명은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물을 유효성분으로 포함하는 피부 미백, 주름, 탄력, 트러블, 또는 항산화용 조성물 (예를 들어, 화장료 조성물)을 제공한다. In order to solve the above-mentioned problems, the present invention provides a method for the production of a medicinal herb, which comprises the steps of: extracting a moth, an extract of a dermis, a medicinal herb extract, a golden extract, a ginseng extract, a yellowish extract, a gardenia extract, (For example, a cosmetic composition) for skin whitening, wrinkling, elasticity, trouble, or antioxidation, which comprises an extract of Ganoderma lucidum, licorice extract, and ginger extract as an active ingredient.
또한, 본 발명은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 생강 추출물, 빈랑 추출물 및 죽력 추출물을 유효성분으로 포함하는 피부 미백, 주름, 탄력, 트러블, 또는 항산화용 조성물 (예를 들어, 화장료 조성물)을 제공한다. The present invention also relates to a method for the production of a medicinal herb extract, a dermis extract, a dermis extract, a thyme extract, a golden extract, a ginseng extract, a yellowish extract, a gardenia extract, a chrysanthemum extract, a chrysanthemum extract, (For example, a cosmetic composition) for skin whitening, wrinkle, elasticity, trouble, or antioxidation, wherein the composition contains ginger extract, buffalo extract and bamboo extract as an active ingredient.
또한, 본 발명은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 생강 추출물, 빈랑 추출물 및 죽력 추출물을 유효성분으로 포함하는 섬유아세포 증식용 화장료 조성물을 제공한다.The present invention also relates to a method for the production of a medicinal herb extract, a dermis extract, a dermis extract, a thyme extract, a golden extract, a ginseng extract, a yellowish extract, a gardenia extract, a chrysanthemum extract, a chrysanthemum extract, The present invention provides a cosmetic composition for the proliferation of fibroblasts, comprising as an active ingredient ginger extract, chewing gum extract, and tabacca extract.
[추출물] [extract]
패모(貝母)는 학명은 Fritillaria verticillata이고, 라틴명은 Fritillariae Bulbus인, 백합과에 속하는 다년생 초본식물이다. 진해, 거담 작용 및 혈압 강하 작용을 하는 것으로 알려져 있다. 한국 북부지방의 심산지역, 함경남도 갑산, 백두산의 산지초원에 자생하고, 중국 동북부, 우수리강에 분포한다. 비늘줄기는 흰색이고 육질이며 5∼6개의 비늘조각으로 되어 있다. 원줄기는 높이 25cm 내외이다. 잎은 마주나거나 3개씩 돌려나고 줄 모양이며, 윗부분에 달린 것은 끝이 안으로 말려서 덩굴손같이 보인다. 잎 끝은 날카롭고 잎자루가 없다.The family name is Fritillaria verticillata , and the Latin name is Fritillariae Bulbus, a perennial herbaceous plant belonging to the lily family. It is known that it plays an active role of ganghae, gangdam and hypotension. It grows in the mountainous prairies of Mt. Shimsan area in the northern part of Korea, Gapsan in South Hamgyong province, and Baekdusan mountain, and it is distributed in the northeastern part of China and the Yizhi River. The stem of the scales is white and fleshy and has 5 to 6 scales. The main stem is about 25cm high. Leaves are opposite, or alternate, with three lines, and the upper part is curled inward and looks like a tendril. The tip of the leaf is sharp and has no petiole.
진피는 귤(Citrus unshiu Markovich)과 병감(Citrus reticulata Blanco)의 과피를 말한다. 라틴명은 Citri Unshius Pericarpium이다. 맛은 쓰고 매우며, 성질은 따뜻하다. 비위가 허약하여 일어나는 구토, 메스꺼움, 소화불량 등에 쓰인다.The dandelion is citrus ( citrus unshiu Markovich ) and the disease ( Citrus reticulata Blanco ). The Latin name is Citri Unshius Pericarpium. The taste is very high, and the quality is warm. Nausea is caused by fragile vomiting, nausea, and indigestion.
황련(黃連)은 라틴명 Coptidis Rhizoma 인, Coptis japonica Makino 중국황련(中國黃連) Coptis chinensis Franchet, 삼각엽황련(三角葉黃連) Coptis deltoidea C. Y. Cheng et Hsiao 또는 운련(雲連) Coptis teeta Wallich (미나리아재비과 Ranunculaceae)의 뿌리줄기로서 뿌리를 제거한 것이다. 세균성 및 아메바성이질, 장염, 폐결핵, 백일해, 성홍열, 대엽성폐염, 급성결막염 등을 치료하는 데 효과가 있다. 중국 원산이며 생약용으로 한국·일본·중국 등지에서 재배하기도 한다. Copenhagen (黄连) is the Latin name Coptidis Rhizoma, Coptis japonica Makino Chinese Coptis (中國 黄连) Coptis chinensis Franchet, triangulated 黄连Coptis deltoidea CY Cheng et Hsiao or 雲 連Coptis The roots of teeta Wallich (Ranunculaceae) were removed. Bacterial and amoebic dysentery, enteritis, pulmonary tuberculosis, pertussis, scarlet fever, lobar pneumonia, acute conjunctivitis and so on. It is native to China and it is cultivated in Korea, Japan, China and so on for herbal medicine.
황금(黃芩)은 라틴명 Scutellariae Radix인, 속썩은풀 Scutellaria baicalensis Georgi (꿀풀과 Labiatae)의 뿌리로서 그대로 또는 주피를 제거한 것이다. 뿌리는 원뿔 모양이고 비틀어져 굽어 있으며, 바깥 면은 황갈색~진한 노란색이고, 질은 단단하면서 취약하고 절단하기 쉽다. 자른 면은 노란색이고, 중심부는 적갈색이다. 냄새가 거의 없고 맛은 약간 쓰다.The golden (黃 芩) is the Latin name Scutellariae Radix, The root of Scutellaria baicalensis Georgi (Lamiaceae and Labiatae) is either removed as it is or is removed. The roots are conical, twisted and curved, and the outer surface is tan to dark yellow. The vagina is firm, vulnerable and easy to cut. The cut surface is yellow and the center is reddish brown. There is little smell and taste is a little bit.
현삼(玄參)은 라틴명 Scrophulariae Radix 인, Scrophularia buergeriana Miquel 또는 중국현삼(中國玄參) Scrophularia ningpoensis Hemsley (현삼과 Scrophulariaceae)의 뿌리를 말한다. 설탕이 타는 것과 같은 특유한 냄새가 있고 맛은 약간 달며 후에 약간 쓰다. 해열제로 인후염 ·종기 ·림프선염에 사용할 수 있다고 보고되고 있다. 산지에서 자란다. The ginseng is the Latin name Scrophulariae Radix, Scrophularia buergeriana Miquel or Chinese ginseng Scrophularia ningpoensis refers to the roots of Hemsley ( hyacinth and Scrophulariaceae). There is a peculiar smell like sugar burning, a little taste and a little bit after. It is reported that it can be used as a fever reducing agent for sore throat, boils, and lymphatic arthritis. It grows in the mountains.
황백(黃栢)은 라틴명 Phellodendri Cortex인, 황벽나무 Phellodendron amurense Ruprecht 또는 황피수 (黃皮樹) Phellodendron chinense Schneider (운향과 Rutaceae)의 줄기껍질로서 주피를 제거한 것이다. 일반 알칼로이드가 지니는 전신작용을 하지 않기 때문에 다량으로 투여해도 부작용이 없으므로 정장제뿐 아니라 건위제로 사용할 수 있다. 또한, 이 약재에 대하여 여러 세균의 내성(耐性)도 생기지 않으므로 유행성 눈병이 유행할 때 세안 소독약으로도 사용할 수 있다. Hwanghaek is the Latin name Phellodendri Cortex, Phellodendron amurense Ruprecht or Phellodendron It is the stem skin of chinense Schneider (Rutaceae and Rutaceae), which removes the juniper. Since the general alkaloid does not have the systemic action, it can be used not only as a topical preparation but also as a side effect agent since it has no side effects even when administered in large amounts. In addition, since this bacterium does not cause resistance to various bacteria, it can be used as a cleansing disinfectant when epidemic eye disease is prevalent.
치자(梔子)는 라틴명 Gardeniae Fructus인, Gardenia jasminoides Ellis (꼭두서니과 Rubiaceae)의 잘 익은 열매로서 그대로 또는 끓는 물에 데치거나 찐 것이다. 「新編中葯志」에 의하면 치자나무 Gardenia jasminoides Ellis는 산치자(山梔子)라 하고, 우리나라 치자 Gardenia jasminoides Ellis var. grandiflora Nakai는 대치자(大梔子) 또는 수치자(水梔子)라 한다고 하였다. 그러나「한국식물명고」에 의하면 두 종은 동일한 종으로 보고 있다. 일본·대만·중국에 분포하며, 열매는 해열, 이담(利膽), 지혈 작용을 하는 것으로 알려져 있다. Gardenia is a ripe fruit of the Latin name Gardeniae Fructus, Gardenia jasminoides Ellis (madder and Rubiaceae), which is either bred or steamed in boiling water. Gardenia jasminoides Ellis is called "Gardenia" and Gardenia jasminoides Ellis var. The grandiflora Nakai is said to be Daisako or Suizuka. However, according to the Korean botanical name, both species are regarded as the same species. It is distributed in Japan, Taiwan and China. Fruit is known to have fever, ejaculation, and hemostasis.
창출(蒼朮)은 라틴명 Atractylodis Rhizoma인, 모창출(茅蒼朮) Atractylodes lancea de Candolle 또는 북창출(北蒼朮) Atractylodes chinensis Koidsumi (국화과 Compositae)의 뿌리줄기이다. 각지의 산에서 널리 자란다. 이뇨 작용, 조혈 자극 작용, 건위(健胃) 작용이 보고되어 있다. 맛은 쓰고 매우며 성질은 따뜻하다. Creation (蒼朮) is the Latin name Atractylodis Rhizoma, Atractylodes lancea de Candolle or north-arctic Atractylodes Chinensis Koidsumi (Chrysanthemum and Compositae) is the rootstock. It grows widely in mountains of various places. Diuretic action, hematopoietic stimulation action, and stomach action have been reported. The taste is very high and the quality is warm.
백출(白朮)은 라틴명 Atractylodis Rhizoma Alba인, 삽주 Atractylodes japonica Koidzumi ex Kitamura 또는 백출(白朮) Atractylodes macrocephala Koidzumi (국화과 Compositae)의 뿌리줄기로서 그대로 또는 주피를 제거한 것이다. 특이한 냄새가 있고 맛은 약간 쓰고 달며 씹으면 점성을 띠고 성질은 따듯하다. 전정작용, 마비 작용을 나타내며, 이뇨 작용 및 혈당 강하 작용, 항암 작용을 하는 것으로 보고되고 있다. Baekchul (白朮) is the Latin name of Atractylodis Rhizoma Alba, sapju Atractylodes japonica Koidzumi ex Kitamura or baekchul (白朮) Atractylodes macrocephala Koidzumi (Chrysanthemum and Compositae) as a root stem or junk is removed. It has a peculiar smell, taste a little bit weary, and if you chew it is viscous and its quality is warm. Vestibular action, diuretic action, hypoglycemic action, and has been reported to have anti-cancer action.
향부자(香附子)는 라틴명 Cyperi Rhizoma 이고, 학명은 Cyperus rotundus Linne (사초과 Cyperaceae)인 사초과에 속하는 다년생 초본식물이다. 뿌리줄기가 옆으로 길게 뻗으며 그 끝부분에 괴경이 생기고 수염뿌리가 내린다. 바닷가 모래땅이나 물가에 살며 제주도에서 나고, 세계의 열대 및 아열대에 분포한다. 통경·건위·진통·진경·행기(行氣)의 효능이 있다Hyangbuja is a Latin name Cyperi Rhizoma and its scientific name is Cyperus It is a perennial herbaceous plant belonging to the genus Rotundus Linne (Quercus and Cyperaceae). The rootstock stretches sideways, with a tuber at its end and a bearded root. They live in the sandy beaches or on the beaches of the sea, come out of Jejudo, and are distributed in the tropical and subtropical regions of the world. There is the efficacy of gyeonggyeonggwa,
생지황(生地黃)은 라틴명 Rehmanniae Radix Recens 이고, Rehmannia glutinosa Liboschitz ex Steudel (현삼과 Scrophulariaceae)의 신선한 뿌리로, 맛은 쓰고 약간 달며 성질은 몹시 차다. 응혈(凝血) 촉진 작용 · 강심(强心) 작용 · 이뇨 작용 · 혈당 강하 작용 · 혈압 상승 작용을 하는 것으로 알려져 있다. It is a fresh name of Rehmanniae Radix Recens and is a fresh root of Rehmannia glutinosa Liboschitz ex Steudel (ginseng and Scrophulariaceae). Its flavor is slightly worn and its quality is very cold. It is known that it acts to promote coagulation (coagulation), strong heart action, diuretic action, hypoglycemic action, and hypertension.
건지황(乾地黃)은 라틴명 Rehmanniae Radix Recens 이고, Rehmannia glutinosa Liboschitz ex Steudel (현삼과 Scrophulariaceae)의 건조한 뿌리로, 맛은 쓰고 약간 달며 성질은 몹시 차다. 자궁출혈, 월경 불순에 사용하는 것으로 보고되고 있다. It is the dry name of Rehmanniae Radix Recens, which is a dried root of Rehmannia glutinosa Liboschitz ex Steudel (Schengenia and Scrophulariaceae). Its taste is slightly worn and its quality is very cold. Uterine bleeding, and menstrual irregularities.
천궁(川芎)은 Cnidium officinale Makino, 중국천궁 (中國川芎) Ligusticum chuanxiong Hort. (산형과 Umbelliferae)의 뿌리줄기로서, 산형과에 속하는 다년생 초본식물. 중국산 식물로 우리나라에서 흔히 재배되며, 약성이 온화하고 맛이 시고, 진정효과 및 조혈효과가 있는 것으로 보고되고 있다. 생것 외에 물에 데쳐 복용하기도 한다. Chengdu (川芎) is a Cnidium officinale Makino, China Taipei (中國 川芎) Ligusticum chuanxiong Hort. (Hill and Umbelliferae), a perennial herbaceous plant belonging to the mountain type. It is a Chinese plant and it is commonly cultivated in Korea. It has been reported that it has mildness, tastiness, soothing effect and hematopoiesis. In addition to raw materials, it is often taken in water.
목향(木香)은 라틴명 Aucklandiae Radix 이고, 초롱꽃목 국화과의 여러해살이풀로, Aucklandia lappa Decaisne(국화과 Compositae)의 뿌리이다. 특유한 냄새가 있고 맛은 약간 쓰다. 발한·이뇨·거담 효과가 있으며, 유럽과 북아시아가 원산지이다. It is a Latin name Aucklandiae Radix, a perennial plant of Asteraceae, Aucklandia lappa is the roots of Decaisne (Compositae). There is a peculiar smell and the taste is slightly bitter. There are effects of sweating, diuretic and gossip, and Europe and northern Asia are the origin.
감초(甘草)는 라틴명 Glycyrrhizae Radix et Rhizoma, Licorice이고, Glycyrrhiza uralensis Fischer, 광과감초(光果甘草) Glycyrrhiza glabra Linne 또는 창과감초(脹果甘草) Glycyrrhiza inflata Batalin (콩과 Leguminosae)의 뿌리 및/또는 뿌리줄기로서 그대로 (즉, 껍질이 붙은 채로) 또는 주피를 제거한 것이다. 특이한 냄새가 나며 맛은 달다. 진해·거담, 근육이완, 이뇨작용을 한다. Licorice is the Latin name Glycyrrhizae Radix et Rhizoma, Licorice, Glycyrrhiza uralensis Fischer, Glycyrrhiza glabra Linne or licorice and licorice Glycyrrhiza inflata Batalin (leguminosae) roots and / or rootstock as it is (ie, with the bark attached) or removed from the juniper. It has a peculiar smell and taste is sweet. Jinhae, geomung, muscle relaxation, diuretic action.
생강(生薑)은 라틴명 Zingiberis Rhizoma Recens 이고, Zingiber officinale Roscoe (생강과 Zingiberaceae)의 생강목 생강과의 여러해살이풀로서, 동남아시아가 원산지이며, 뿌리줄기는 납작하게 눌려있거나 불규칙한 덩어리 모양이며 대개는 갈라졌거나 또는 갈라진 덩어리이다. 특유한 냄새가 나고 맛은 매우 맵다. 위액분비촉진, 소화력 증진, 심장흥분 작용, 혈액순환촉진, 억균작용이 보고되어 있다. The ginger is the Latin name Zingiberis Rhizoma Recens, Zingiber It is a perennial plant of officinale Roscoe (ginger and Zingiberaceae) with ginger tree ginger. Origin of Southeast Asia. Rootstock is a flattened or irregular lumpy shape, usually a split or cracked mass. The smell is distinctive and the taste is very spicy. Promoting gastric secretion, promoting digestive power, promoting cardiac stimulation, promoting blood circulation, and inhibiting activity.
빈랑(檳)은 라틴명 Areca Arecae Semen 이고, 종려목 야자나무과 교목으로, 말레이시아 원산이며, Areca catechu Linn (야자과 Palmae)의 잘 익은 씨로서 열매를 채취하여 물에 삶아 열매껍질을 벗긴 것이다. 종피는 외층과 내층으로 나누어진다. 외층은 여러 층의 가로로 배열한 납작한 석세포로 조성되어있고 그 안에는 갈색물질(tannin)이 들어있다. 석세포는 크기가 일정치 않으며 보통 세포간극을 볼 수 있다. 매 층은 갈색물질(tannin)이 들어있는 직사각형의 유세포로 조성되어있고 그 중에는 소수의 유관속이 흩어져 있으며 세포간극은 없다. 착입조직(錯入組織)은 종피 내층이 배유까지 뻗어 들어가서 형성된 것인데. 세포중의 대부분에는 갈색물질이 들어있다. 약간 특유한 냄새가 있으며 맛은 떫고 약간 쓰다. It is a Latin name Areca Arecae Semen, a palm-tree palm tree, native to Malaysia, ripe seeds of Areca catechu Linn (palm and Palmae), harvested and boiled in water. The seed coat is divided into an outer layer and an inner layer. The outer layer is composed of flat stone cells arranged horizontally in several layers and contains brown substance (tannin). Stone cells are not uniform in size and can usually be seen in cell spaces. Each layer is composed of rectangular flow cells containing tannin, with a small number of vascular channels scattered and no cell gap. The entrapped tissue is formed by the inner layer of the seed coat extending into the endosperm. Most of the cells contain brown substances. There is a slight peculiar odor, and the taste is slightly worn.
죽력(竹瀝)은 라틴명 Bambusae Succus 이고, 솜대 Phllylostachys nigra Munro var. henonis Stapf 또는 왕대 Phyllostachys bambusoides Sieb. et Zucc. (벼과 Gramineae)의 줄기에 열을 가할 때 유출되는 즙액이다. 맑은 황색 내지 황갈색이며 투명하다. 타는 냄새가 나고 맛은 담담하다. 알코올분해작용, 항균작용, 콜레스테롤강하작용이 보고되었다.The tabasheer is the Latin name Bambusae Succus, the scabbard Phllylostachys There is nigra Munro. henonis Stapf or throne Phyllostachys bambusoides Sieb. et Zucc. (Gramineae, Gramineae) is a juice that flows out when you apply heat to the stem. It is clear yellow to yellowish brown and transparent. I smell burning and the taste is cool. Alcohololytic, antibacterial, and cholesterol-lowering effects were reported.
본 발명자들은 상기 추출물의 모두가 피부에 유익한 생물학적 활성을 가지며, 상기 추출물 중 2이상의 복합 추출물, 바람직하게 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물의 복합 추출물, 가장 바람직하게, 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 생강 추출물, 빈랑 추출물 및 죽력 추출물의 복합 추출물은 시너지적 생물학적 활성을 가짐을 발견하였다. The present inventors have found that all of the above extracts have a biological activity beneficial to the skin, and that the extracts of two or more of the above extracts, preferably the extracts of mulberry, dermis, chrysanthemum, Extracts of mulberry leaves, extracts of mulberry leaves, extracts of mulberry leaves, extracts of golden mulberry leaves, extracts of mulberry leaves, extracts of yellow mulberry leaves, extracts of mulberry leaves, mulberry leaves, mulberry leaves, It was found that the combined extract of Gardenia extract, Creation extract, Lycoris spp., Herbal extract, Lycoris spp. Extract, Dried persimmon extract, Cucurbit extract, Mokchee extract, Licorice extract, Ginger extract, Anthelmintic extract and Capsicum extract had synergistic biological activity.
본 발명에 있어서, 용어 "추출물"은 상기 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농충액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.In the present invention, the term "extract" means an extract obtained by extracting the extract, a dilute or concentrated solution of the extract, a dried product obtained by drying the extract, a controlled preparation or a purified product of the extracted solution, Itself and extracts of all formulations which can be formed using extracts.
상기 추출물에는 각각의 식물을 설명하며 특정된 부위 외에도 그의 잎, 줄기, 나무껍질, 뿌리, 꽃 또는 꽃눈, 과실, 종자, 수액 및 전체 식물이 포함될 수 있다. Each of the above-mentioned extracts describes each plant and may include leaves, stems, bark, roots, flowers or flowers, fruit, seeds, sap, and whole plants in addition to the specified parts.
상기 추출물을 제조하기 위하여, 통상의 기술자는 당업계에 공지된 임의의 적합한 방법을 사용할 수 있다. 예를 들어, 용매 추출법에 의할 수 있다. 식물 전체 또는 임의의 부분을 분쇄한 다음(예를 들어, 블렌더), 추출 용매를 처리하여, 용매 추출물을 수득할 수 있다. 분쇄 전에 건조 과정(예를 들어, 40 내지 70℃에서 15 내지 50시간 동안의 건조)을 거친 다음 분쇄할 수도 있다. 또한, 용매 추출물은 감압 증류 및 동결건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. In order to prepare the above extract, one of ordinary skill in the art can use any suitable method known in the art. For example, a solvent extraction method can be used. The entire plant or any portion thereof may be ground (e.g., a blender) and then the extraction solvent may be treated to obtain a solvent extract. It may be subjected to a drying process (for example, drying at 40 to 70 DEG C for 15 to 50 hours) before pulverization and then pulverization. In addition, the solvent extract may be prepared in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying.
상기 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1 내지 C4의 저급 알코올; 글리세린, 부틸렌글라이콜, 프로필렌글라이콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게, 물, 저급알코올을 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있다. 상기 용매를 사용하여 1회 이상 추출하여 용매 추출물을 제조할 수 있으며, 상기 용매 추출물을 감압 증류한 후 동결건조 또는 분무 건조하여 얻은 건조 추출물을 제조할 수 있다. The kind of the extraction solvent used is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; And hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or mixtures thereof. Water and lower alcohols may be used alone or in combination of two or more. The solvent extract may be prepared by extracting the extract at least one time using the solvent, and the dry extract obtained by vacuum distillation or spray drying the solvent extract may be prepared.
상기 추출 용매의 양은 이용되는 추출 용매의 종류에 따라 다양할 수 있으나, 예를 들어 대상 식물의 건조 중량에 대하여 1 내지 20배, 또는 5 내지 20배로 사용할 수 있다. The amount of the extraction solvent may vary depending on the kind of the extraction solvent used, but may be, for example, 1 to 20 times, or 5 to 20 times the dry weight of the target plant.
이외에도, 당업계 공지된 다양한 추출 공정, 예를 들어, 온침(maceration), 인퓨전(infusion), 퍼콜레이션(percolation), 소화, 전즙(decoction), 고온 연속 추출(hot continuous extraction), 수성-알코올성 추출, 역류 추출, 마이크로파 보조 추출, 초음파 추출, 초임계 유체 추출, 조직편 추출(phytonic extract) (예를 들어, 하이드로-플루오로-카본 용매) 등) 등을 선택하여 사용할 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다.In addition, various extraction processes known in the art such as, for example, maceration, infusion, percolation, digestion, decoction, hot continuous extraction, aqueous- (For example, hydrofluoro-carbon solvent), etc.), which may be used alone or in combination with one another, may be used, for example, May be carried out by using two or more methods in combination.
[조성물][Composition]
본 발명에 따른 조성물은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물을 유효성분으로 포함한다. 더욱 바람직하게, 빈랑 추출물 및 죽력 추출물을 추가로 유효성분으로 포함할 수 있다. The composition according to the present invention can be used as an effective ingredient for the prevention and treatment of various diseases such as feverfew, dandruff extract, hwangryun extract, golden extract, ginseng extract, Huangbai extract, gardenia extract, , And ginger extract as active ingredients. More preferably, the bilberry extract and the bamboo extract may be further contained as an active ingredient.
본 발명에 있어서 "유효성분으로 포함된다"는 의미는 본 발명에 따른 조성물로부터 피부 개선 효과를 나타낼 수 있는 정도로, 추출물이 첨가되는 것을 의미하고, 피부 전달 및 안정화 등을 위하여 다양한 성분을 부성분으로 첨가하여 다양한 형태로 제형화(formulation) 가능함을 포함하는 의미이다.In the present invention, the term "included as an active ingredient" means that the extract is added to the skin composition of the present invention to such an extent that it can exhibit a skin improving effect, and various components are added as a sub ingredient And it is possible to formulate in various forms.
본 발명에 따른 조성물에 각각의 식물 추출물은 다음과 같은 비율로 포함될 수 있다. 예를 들어, 패모 추출물: 진피 추출물: 황련 추출물: 황금 추출물: 현삼 추출물: 황백 추출물: 치자 추출물: 창출 추출물: 백출 추출물: 향부자 추출물: 생지황 추출물: 건지황 추출물: 천궁 추출물: 목향 추출물: 감초 추출물: 생강 추출물의 중량비는 1: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10, 또는 1: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10, 또는 1: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5 또는 1: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3으로 포함될 수 있다. Each plant extract may be included in the composition according to the present invention in the following proportions. For example, the extracts of mulberry extracts: dermis extracts: Huangryu extract: golden extracts: ginseng extracts: yellowish white extracts: gardenia extracts: extracts extracts: 10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10, 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10, or 1: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3 can be included.
또한, 패모 추출물: 진피 추출물: 황련 추출물: 황금 추출물: 현삼 추출물: 황백 추출물: 치자 추출물: 창출 추출물: 백출 추출물: 향부자 추출물: 생지황 추출물: 건지황 추출물: 천궁 추출물: 목향 추출물: 감초 추출물: 생강 추출물: 빈랑 추출물: 죽력 추출물의 중량비는 1: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10:0.01 ~ 10, 또는 1: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10, 또는 1: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5:1 ~ 5 또는 1: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3의 범위로 포함될 수 있다. Extract of Ganoderma lucidum: Extract of Ganoderma lucidum Extract: Extract of Ganoderma lucidum Extract: Extract of Ganoderma lucidum Extract: Extract of Ganoderma lucidum Extract: Ganoderma Extract: Ginger Extract: 10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5 or 1: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: Can.
본 발명에 따른 조성물은 이의 최종 형태 중에 적어도 약 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%, 0.0054%, 0.0055%, 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%, 0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650%, 0.0675%, 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000%, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%, 0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%, 0.5250%, 0.550%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% 또는 99% 이상의 범위로 본 발명의 1 이상의 추출물을 포함할 수 있다. The compositions according to the present invention may contain at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012% , 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026% %, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042% 0.005%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0058% , 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077% %, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095% 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275 %, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650% 0.0725%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000% , 0.2250, 0.2500, 0.2750, 0.3000, 0.3250, 0.3500, 0.3750, 0.4000, 0.4250, 0.4500, 0.4750, 0.5000, 0.5250, 0.550, 0.5750, 0.6000, 0.6250 %, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0% 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% , 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2% 5.4%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2% 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7% , 7.9%, 8. 9.2%, 9.4%, 9.4%, 9.5%, 9.6%, 8.3%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0% , 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21% %, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75% 85%, 90%, 95%, or 99% or more of the extract of the present invention.
또한, 본 발명에 따른 조성물에는 본 발명의 각각의 추출물이 조성물의 최종 형태 중에 적어도 약 0.0001% ~ 90%, 0.001% ~ 90%, 0.01% ~ 90%, 0.1% ~ 90%, 0.1% ~ 90%, 0.1% ~ 80%, 0.1% ~ 70%, 0.1% ~ 60%, 0.1% ~ 50%, 0.1% ~ 40%, 0.1% ~ 30%, 0.1% ~ 20% 또는 0.1% ~ 10%의 범위로 포함될 수 있다. The composition according to the present invention may also contain at least about 0.0001% to 90%, 0.001% to 90%, 0.01% to 90%, 0.1% to 90%, 0.1% to 90% %, 0.1 to 80%, 0.1 to 70%, 0.1 to 60%, 0.1 to 50%, 0.1 to 40%, 0.1 to 30%, 0.1 to 20% or 0.1 to 10% . ≪ / RTI >
상기 %는 조성물의 총 중량 대비 중량 또는 총 부피 대비 부피를 기준으로 계산할 수 있으며, 농도는 조성물의 목적하는 효과 또는 조성물이 혼입되는 제품에 따라 조정될 수 있다. The% can be calculated on the basis of the total weight of the composition or the volume relative to the total volume, and the concentration can be adjusted according to the desired effect of the composition or the product into which the composition is incorporated.
본 발명의 조성물은 모든 유형의 비히클 내로 제형화될 수 있다. 적합한 비히클의 예로는 에멀젼 (예를 들어, 수중유, 유중수, 수중실리콘, 실리콘중수, 수중유중수, 수중유, 유중수중유, 실리콘중수중유 등), 크림, 로션, 용액 (예컨대, 수성 및 하이드로-알코올 용액), 무수 베이스 (예를 들어, 립스틱 및 파우더), 젤, 연고, 페이스트, 밀크, 액체, 에어로졸, 고체 형태 또는 아이 젤리를 포함하나, 이에 제한되지 않는다. The compositions of the present invention may be formulated into any type of vehicle. Examples of suitable vehicles include, but are not limited to, emulsions (e.g., oil, water, water in silicone, water in silicone, water in heavy oil, water in oil, water in heavy water, But are not limited to, a hydro-alcoholic solution), a dry basis (e.g., lipstick and powder), a gel, ointment, paste, milk, liquid, aerosol, solid form or eye jelly.
또한, 본 발명의 조성물은 피부와 같은 표적 영역으로의 운반을 위해 캡슐화될 수도 있다. 캡슐화 기술은 예를 들어, 피부에 성분을 전달하는 운반 비히클로서 사용될 수 있는 리포좀, 소낭, 및/또는 나노입자 (예를 들어, 성분이 트랩핑(trap되고, 캡슐화되고/되거나 흡수되는 폴리머 물질을 포함하는 생분해성 및 비생분해성 콜로이드성 입자, 예를 들어 나노스피어(nanosphere) 및 나노캡슐을 포함)의 사용을 포함할 수 있으나, 이에 제한되지 않는다.The compositions of the present invention may also be encapsulated for delivery to a target area, such as the skin. Encapsulation techniques include, for example, the use of liposomes, follicles, and / or nanoparticles (e. G., Components that are trapped, encapsulated, and / or absorbed polymeric materials that can be used as a delivery vehicle But are not limited to, the use of biodegradable and non-biodegradable colloidal particles, including, for example, nanospheres and nanocapsules.
본 발명에 따른 조성물은 다양하게 제품화될 수 있다. 예를 들어, 화장료 조성물, 식품 조성물 등으로 제품화될 수 있다. The composition according to the present invention can be variously commercialized. For example, cosmetic compositions, food compositions, and the like.
상기 화장료 조성물은 예를 들어, 일반적인 유화 제형 및 가용화 제형의 형태로 제조된 것일 수 있다. 예를 들어, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이크림, 마사지 크림 등과 같은 크림, 에센스, 세럼, 화장연고, 스프레이, 오일젤, 젤, 팩, 선 스크린, 메이크업베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있으나, 이에 제한되지 않고 당업계 공지된 다양한 형태로 제형화될 수 있다. The cosmetic composition may be prepared, for example, in the form of a general emulsified formulation and a solubilized formulation. For example, creams, essences, serums, cosmetic ointments, sprays, oil gels, gels such as lotions such as lotion, facial lotion, body lotion and the like such as flexible lotion or nutrition lotion, nutrition cream, A lotion, a cleansing lotion, a makeup remover such as a cleansing oil, a cleansing foam, a soap, a body wash and the like such as a foundation, a pack, a sunscreen, a makeup base, a liquid type, a solid type or a spray type, But may be formulated into various forms known in the art without limitation.
상기 화장료 조성물에는 본 발명의 목적을 해하지 않는 이상, 본 발명에 따른 추출물 외에 당업계에서 화장료 조성물의 성분으로 공지된 통상의 성분을 임의로 선택하여 추가로 포함할 수 있다. 예를 들어, 방향제 (합성 및 천연), 염료 및 색 성분, 흡수제, 에멀젼화제, 안정화제, 윤활제, 용매, 보습제 (예: 연화제(emollient), 습윤제(humectant), 피막형성제, 폐색제(occlusive agent), 및 피부의 천연 보습 메커니즘에 영향을 주는 작용제(agent)를 포함함), 발수제(water-repellant), UV 흡수제 (물리적 및 화학적 흡수제, 예를 들어 파라아미노벤조산("PABA") 및 상응하는 PABA 유도체, 이산화티탄, 산화아연 등), 에센셜 오일(essential oil), 비타민 (예: A, B, C, D, E 및 K), 미량 금속 (예: 아연, 칼슘 및 셀레늄), 항-자극제(anti-irritant) (예: 스테로이드 및 비스테로이드성 항염증제), 항-미생물제(anti-microbial agent), 항산화제 (예: BHT 및 토코페롤), 킬레이트제 (예: 다이소듐 EDTA 및 테트라소듐 EDTA), 보존제 (예: 메틸파라벤 및 프로필파라벤), pH 조정제 (예: 수산화나트륨 및 시트르산), 흡수제(예를 들어, 알루미늄 전분 옥테닐석시네이트, 카올린, 옥수수 전분, 귀리 전분, 사이클로덱스트린, 탈크(talc), 및 제올라이트), 피부 블리칭(bleaching) 및 라이트닝(lightening) 작용제 (예를 들어, 하이드로퀴논 및 니아신아미드 락테이트), 습윤제 (예: 글리세린, 프로필렌 글리콜, 부틸렌 글리콜, 펜틸렌 글리콜, 소르비톨, 우레아 및 만니톨), 각질제거제(exfoliant) (예: 알파-하이드록시산 및 베타-하이드록시산, 예를 들어 락트산, 글리콜산 및 살리실산; 및 이들의 염), 발수제(waterproofing agent) (예: 마그네슘/알루미늄 하이드록시드 스테아레이트), 피부 컨디셔닝제(skin conditioning agent) (예: 알로에 추출물, 알란토인(allantoin), 비사볼롤(bisabolol), 세라마이드(ceramide), 다이메티콘, 히알루론산, 및 다이포타슘 글리시리제이트), 및 증점제(thickening agent) (예:조성물의 점도를 증가시킬 수 있는 물질, 예를 들어 카복실산 폴리머, 가교된 폴리아크릴레이트 폴리머, 폴리아크릴아미드 폴리머, 다당류 및 검(gum)) 및 실리콘 함유 화합물(예: 실리콘 오일 및 폴리오르가노실록산) 등이 포함될 수 있다. In addition to the extract according to the present invention, the above-mentioned cosmetic composition may further include optional ingredients commonly known as ingredients of the cosmetic composition in the art, so long as the object of the present invention is not impaired. Emulsifying agents, stabilizers, lubricants, solvents, moisturizers (e.g. emollients, humectants, film forming agents, occlusive agents, emulsifiers, water-repellant, a UV absorber (including physical and chemical absorbents such as para-aminobenzoic acid ("PABA") and corresponding (Eg, PABA derivatives, titanium dioxide, zinc oxide, etc.), essential oils, vitamins such as A, B, C, D, E and K, trace metals such as zinc, calcium and selenium, Antioxidants (such as BHT and tocopherol), chelating agents (such as disodium EDTA and tetrasodium EDTA), antioxidants (for example, antimicrobial agents) , Preservatives (such as methylparaben and propylparaben), pH adjusting agents (such as sodium hydroxide and citric acid) (E.g., aluminum starch octenyl succinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolites), skin bleaching and lightening agents (e.g., Hydroquinone and beta-hydroxynaphthoic acid (e.g., hydroquinone and niacinamide lactate), wetting agents such as glycerin, propylene glycol, butylene glycol, pentylene glycol, sorbitol, urea and mannitol, exfoliants (E.g., magnesium / aluminum hydroxide stearate), skin conditioning agents (e.g., aloe extracts), and the like, , Allantoin, bisabolol, ceramide, dimethicone, hyaluronic acid, and dipotassium glycyrrhizate), and thickening agents (e.g., (E.g., silicone oils and polyorganosiloxanes), and the like, which are capable of increasing viscosity, such as carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides and gums, .
상기 식품 조성물은 예를 들어, 음료, 강화수(fortified water), 에너지 드링크(energy drink), 영양 드링크(nutritional drink), 고형 식품, 비타민, 보조제(Supplement) 등) 등으로 제형화 될 수 있으나, 이에 제한되지 않는다. 상기 보조제에는 비타민, 무기질, 허브 또는 기타 식물, 아미노산, 효소 및 대사산물을 포함할 수 있다. 이러한 보조제는 경구 이용(oral consumption)에 적합하며, 경구로 투여될 수 있다.The food composition may be formulated into, for example, beverages, fortified water, energy drinks, nutritional drinks, solid foods, vitamins, supplements, etc., But is not limited thereto. Such adjuvants may include vitamins, minerals, herbs or other plants, amino acids, enzymes and metabolites. Such adjuvants are suitable for oral consumption and may be administered orally.
본 발명에 따른 조성물을 포함하는 키트로 제공될 수 있다. 본 발명에 따른 조성물은 용기에 포함되며, 용기는 병, 금속 튜브, 라미네이트 튜브, 플라스틱 튜브, 디스펜서, 압력 용기, 장벽 용기, 패키지, 컴파트먼트, 립스틱 용기, 컴팩트 용기, 화장용 조성물을 담을 수 있는 화장용 팬, 또는 다른 타입의 용기 예를 들어, 분산매체(dispersions) 또는 조성물 또는 유지되는 바람직한 병, 디스펜서, 또는 패키지 내로 주입 또는 블로우-몰드된 플라스틱 용기 등이 포함될 수 있으며, 이에 제한되지 않는다. 상기 키트에는 키트 또는 조성물을 사용하기 위한 지시서가 포함될 수 있으며, 지시서는 별개 용지에 기재될 수 있고, 또는 용기 표면, 용기 포장지의 표면 상에 기재될 수 있다. 지시사항은 글자, 어구, 약어, 그림 또는 기호 등이 포함되며, 이에 제한되지 않는다. 지시서에는 예를 들어, 키트 또는 조성물의 사용 방법, 적용 방법 및 유지 방법 등에 관한 지시사항이 포함될 수 있다. 용기에는 사전에 정해진 양에 따라 분배하여 담을 수 있다. May be provided as a kit comprising the composition according to the present invention. The composition according to the invention is contained in a container which can contain a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressure vessel, a barrier container, a package, a compartment, a lipstick container, a compact container, A cosmetic pan, or other type of container, including, but not limited to, a plastic container that is injected or blow-molded into a suitable bottle, dispenser, or package to be maintained or dispersed, . The kit may include an instruction for using the kit or composition, the instruction sheet may be described on a separate sheet, or may be described on the surface of the container surface, the surface of the container wrapper. Instructions include, but are not limited to, letters, phrases, abbreviations, pictures or symbols. The instructions may include, for example, instructions on how to use, apply and maintain the kit or composition. The container can be dispensed according to a predetermined amount.
본 발명에 따른 조성물은 국소용 피부 조성물로 제공될 수 있다. The composition according to the present invention may be provided as a topical skin composition.
또한, 본 발명에 따른 조성물을 피부에 국소 적용하는 방법을 제공할 수 있다. In addition, a method of topically applying the composition according to the present invention to the skin can be provided.
본 발명에 있어서, 용어 "국소 적용"은 조성물을 각질 조직의 표면상에 적용하거나 도포하는 것을 의미하고, "국소용 피부 조성물"은 각질 조직상에 국소 적용 또는 도포하기에 적합한 조성물을 포함한다. 이러한 조성물은 피부에 적용되는 경우 과도한 독성, 부적합성(incompatibility), 불안정성, 알러지 반응 등을 갖지 않는다는 점에서, 전형적으로 피부과학적으로 허용된다. 본 발명의 국소 피부 케어 조성물은, 피부에 적용된 후 현저한 적하(dripping) 또는 풀링(pooling)을 회피하기 위해, 선택된 점도를 지닐 수 있다.In the present invention, the term "topical application" means applying or applying the composition on the surface of keratinous tissue, and "topical skin composition" includes compositions suitable for topical application or application on keratinocytes. Such compositions are typically dermatologically acceptable in that they do not have excessive toxicity, incompatibility, instability, allergic response, etc. when applied to the skin. The topical skin care compositions of the present invention may have a selected viscosity to avoid significant dripping or pooling after application to the skin.
[피부 개선 효과][Skin improvement effect]
본 발명에 따른 조성물은 생물학적 활성을 가지며, 피부 개선에 우수한 효과를 발휘한다. The composition according to the present invention has biological activity and exerts excellent effects on skin improvement.
보다 구체적으로, 본 발명에 따른 조성물은 피부 미백 효과가 있다. More specifically, the composition according to the present invention has a skin whitening effect.
상기 피부 미백은 멜라닌 형성 과정을 억제 시켜 멜라닌 생성을 억제하는 것을 말한다. The skin whitening refers to inhibiting melanin formation and inhibiting melanin formation.
본 발명자들은 본 발명에 따른 복합 추출물을 멜라노마 세포에 처리하여 생성된 멜라닌의 양을 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 멜라닌 생성 억제 효과를 보임을 확인할 수 있었고, 피부 미백 효과가 공지되어 있는 알부틴에 상응하는 효과를 발휘함을 알 수 있었다. 본 발명에 따른 조성물은 멜라닌 생성 저해 효과가 뛰어나, 우수한 미백 효과를 나타냄을 확인하였다. As a result of measuring the amount of melanin produced by treating the melanoma cells according to the present invention, the inventors of the present invention confirmed that the melanin production inhibitory effect was enhanced compared with the case of treating each extract, It was found that the effect exerted an effect corresponding to known arbutin. It was confirmed that the composition according to the present invention was excellent in the effect of inhibiting melanin formation and exhibited excellent whitening effect.
또한, 본 발명에 따른 조성물은 주름 및 탄력 개선 효과가 있다. In addition, the composition according to the present invention has an effect of improving wrinkles and elasticity.
상기 피부 주름이란 피부가 쇠하여 생긴 잔줄을 의미하며, 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐과 엘라스틴의 감소, 외부환경 등에 의해 유발될 수 있다. The skin wrinkles are caused by the skin of the skin and can be caused by the cause of the gene, collagen and elastin present in the skin dermis, and the external environment.
상기 주름 개선은 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.The wrinkle improvement refers to suppressing or inhibiting the generation of wrinkles, or alleviating the already generated wrinkles.
상기 피부 탄력이란 진피층에 존재하는 엘라스틴(elastin)으로 구성된 탄력섬유 및 콜라겐(collagen)이라고 하는 교원섬유에 의해 나타나는 것으로, 상기 탄력 개선이란 탄력 감소를 억제 또는 저해하거나, 탄력을 유지 또는 향상시키는 것을 말한다.The skin elasticity refers to elastic fibers composed of elastin existing in the dermal layer and collagen fibers called collagen. The elasticity improvement refers to suppressing or inhibiting elasticity reduction or maintaining or improving elasticity .
본 발명자들은 본 발명에 따른 복합 추출물을 처리한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 콜라겐 합성 촉진 효과 및 엘라스타제 활성 저해 효과를 보임을 확인할 수 있었고, 피부 콜라겐 합성 촉진 효과가 공지되어 있는 비타민 C에 상응하는 효과를 보이며, 피부 엘라스타제 활성 저해 효과가 공지되어 있는 퀘세틴에 상응하는 효과를 발휘함을 알 수 있었다. 본 발명에 따른 조성물은 콜라겐 합성 촉진 효과 및 엘라스타제 활성 저해 효과가 뛰어나, 우수한 피부 주름 및 탄력 개선 효과를 나타냄을 확인하였다. As a result of treating the complex extract according to the present invention, the present inventors confirmed that they exhibited an enhanced collagen synthesis promoting effect and an elastase activity inhibiting effect, respectively, as compared with the case of treating each extract, And the effect of inhibiting the activity of skin elastase was shown to exert an effect corresponding to the known quercetin. The composition according to the present invention is excellent in collagen synthesis promoting effect and elastase activity inhibiting effect and shows excellent wrinkles and elasticity improving effect.
또한, 본 발명에 따른 조성물은 트러블 개선 효과가 있다. Further, the composition according to the present invention has an effect of improving the trouble.
상기 트러블은 피부자극 및 염증과 같은 증상을 말하며, 염증 반응에는 외부 자극에 의한 동통, 발열, 발적, 종창, 기능상실 등을 특징으로 하며, 조직학적으로는 소동맥, 모세혈관 및 소정맥의 투과성과 혈류증가를 동반한 확장, 혈장단백을 함유한 혈장의 삼출, 백혈구의 염증부위로의 이동 등을 포함한 복잡한 증상 등이 관찰되며, 피부자극 반응에는 홍반, 가려움, 발열 등을 특징으로 한다. The above-mentioned troubles are symptoms such as skin irritation and inflammation. The inflammatory reaction is characterized by pain, fever, redness, swelling and malfunction due to external stimuli. Histologically, the permeability of the arterioles, capillaries, , Complicated symptoms including enlargement accompanied by increase, excretion of plasma containing plasma protein, migration to inflammation site of leukocyte, and skin irritation reaction are characterized by erythema, itching, fever and the like.
상기 트러블 개선은 피부 자극 반응 및 염증 반응을 억제 또는 저해하거나, 이미 진행 중인 피부자극 반응 또는 염증 반응을 완화시키는 것을 말한다.The improvement of the trouble refers to inhibiting or inhibiting the skin irritation reaction and the inflammation reaction, or alleviating the skin irritation reaction or the inflammation reaction already in progress.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 NO 생성 저해 효과를 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 NO 생성 저해 효과를 보임을 확인할 수 있었고, NO 생성 저해 효과가 공지되어 있는 L-NMMA에 상응하는 효과를 발휘함을 알 수 있었다. 본 발명에 따른 조성물은 NO 생성 저해를 통해 우수한 피부 트러블 개선 효과를 나타냄을 확인하였다. As a result of measuring the inhibitory effect on NO production by treating the compound extract according to the present invention, the present inventors confirmed that the inhibitory effect on NO production was enhanced compared to the case of treating each extract, and NO inhibitory effect was known And exhibited an effect corresponding to that of L-NMMA. It was confirmed that the composition according to the present invention exhibits excellent skin trouble improving effect through inhibition of NO production.
또한, 본 발명에 따른 조성물은 항산화 효과가 있다. In addition, the composition according to the present invention has an antioxidative effect.
상기 항산화는 세포내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species;ROS)에 의한 세포의 산화를 억제하는 것을 말하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다. The antioxidant refers to inhibition of cellular oxidation by free radicals or reactive oxygen species (ROS), which are highly reactive according to oxidative stress caused by intracellular metabolism or ultraviolet rays, and free radicals Or removal of reactive oxygen species, thereby reducing damage to the cells.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 자유라디칼 소거능을 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 자유라디칼 소거능을 보임을 확인할 수 있었고, 자유라디칼 소거능이 공지되어 있는 비타민 C에 상응하는 효과를 발휘함을 알 수 있었다. 이로써, 본 발명에 따른 조성물은 우수한 항산화 효과를 나타냄을 확인하였다. As a result of measuring the free radical scavenging ability of the complex extract according to the present invention, the inventors of the present invention confirmed that they exhibited an increased free radical scavenging ability as compared with the case of treating each extract, and found that the free radical scavenging ability of vitamin C And the effect is comparable to that of the conventional method. Thus, it was confirmed that the composition according to the present invention exhibits an excellent antioxidative effect.
또한, 본 발명에 따른 조성물은 항당화 효과가 있다. In addition, the composition according to the present invention has an antiherating effect.
상기 당화는 과도한 당의 존재로 인해 생기는 당과 단백질이 결합해 단백질이 파괴되는 현상을 말한다. 당화가 진행되면 콜라겐과 엘라스틴에 영향을 미쳐 피부 탄력 저하외 각종 피부손상을 일으키게 된다. The glycation refers to a phenomenon in which a sugar and a protein are bound to each other due to the presence of excessive sugars and the protein is destroyed. As glycosylation progresses, it affects collagen and elastin, resulting in skin elasticity deterioration and other skin damage.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 항당화 효과를 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 항당화 효과를 보임을 확인할 수 있었고, 항당화 효과가 공지되어 있는 아미노구아니딘에 상응하는 효과를 발휘함을 알 수 있었다. 이로써, 본 발명에 따른 조성물은 우수한 항당화 효과를 나타냄을 확인하였다. As a result of measuring the antagonism effect by treating the complex extract according to the present invention, the inventors of the present invention have confirmed that they exhibit an elevated antihyperglycosylation effect as compared with the case of treating the respective extracts, and the aminoguanidine And the effect is comparable to that of the conventional method. Thus, it was confirmed that the composition according to the present invention exhibits excellent anticarcinogenic effect.
또한, 본 발명에 따른 조성물은 섬유아세포 증식 효과가 있다. In addition, the composition according to the present invention has a fibroblast proliferation effect.
본 발명에 따른 조성물 중에서도 '패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물'과 '빈랑 추출물 및 죽력 추출물'을 모두 포함하는 조성물에서 나타나는 효과이다. Among the compositions according to the present invention, the composition according to the present invention can be applied to a variety of compositions such as' mulberry extract, dermis extract, Huangyu extract, golden extract, ginseng extract, Huangyu extract, gardenia extract, Extracts, and ginger extracts', and 'bilberry extract and bamboo extract'.
본 발명에 따른 조성물은 in vitro 또는/및 in vivo에서 섬유아세포 증식에 사용될 수 있다. The composition according to the present invention may be used for fibroblast proliferation in vitro and / or in vivo.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 세포증식율을 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 세포증식효과를 보임을 확인할 수 있었고, 이로써 본 발명에 따른 조성물은 우수한 섬유아세포 증식 효과를 나타냄을 확인하였다. As a result of measuring the cell proliferation rate by treating the complex extract according to the present invention, the present inventors have confirmed that the extract according to the present invention exhibits an increased cell proliferation effect as compared with the case of treating each extract, Proliferative effect was confirmed.
상술한 과제를 해결하기 위하여, 본 발명은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물을 유효성분으로 포함하는 피부 미백, 주름, 탄력, 트러블, 또는 항산화용 조성물 (예를 들어, 화장료 조성물)을 제공한다. In order to solve the above-mentioned problems, the present invention provides a method for the production of a medicinal herb, which comprises the steps of: extracting a moth, an extract of a dermis, a medicinal herb extract, a golden extract, a ginseng extract, a yellowish extract, a gardenia extract, (For example, a cosmetic composition) for skin whitening, wrinkling, elasticity, trouble, or antioxidation, which comprises an extract of Ganoderma lucidum, licorice extract, and ginger extract as an active ingredient.
또한, 본 발명은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 생강 추출물, 빈랑 추출물 및 죽력 추출물을 유효성분으로 포함하는 피부 미백, 주름, 탄력, 트러블, 또는 항산화용 조성물 (예를 들어, 화장료 조성물)을 제공한다. The present invention also relates to a method for the production of a medicinal herb extract, a dermis extract, a dermis extract, a thyme extract, a golden extract, a ginseng extract, a yellowish extract, a gardenia extract, a chrysanthemum extract, a chrysanthemum extract, (For example, a cosmetic composition) for skin whitening, wrinkle, elasticity, trouble, or antioxidation, wherein the composition contains ginger extract, buffalo extract and bamboo extract as an active ingredient.
또한, 본 발명은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 생강 추출물, 빈랑 추출물 및 죽력 추출물을 유효성분으로 포함하는 섬유아세포 증식용 화장료 조성물을 제공한다.The present invention also relates to a method for the production of a medicinal herb extract, a dermis extract, a dermis extract, a thyme extract, a golden extract, a ginseng extract, a yellowish extract, a gardenia extract, a chrysanthemum extract, a chrysanthemum extract, The present invention provides a cosmetic composition for the proliferation of fibroblasts, comprising as an active ingredient ginger extract, chewing gum extract, and tabacca extract.
[추출물] [extract]
패모(貝母)는 학명은 Fritillaria verticillata이고, 라틴명은 Fritillariae Bulbus인, 백합과에 속하는 다년생 초본식물이다. 진해, 거담 작용 및 혈압 강하 작용을 하는 것으로 알려져 있다. 한국 북부지방의 심산지역, 함경남도 갑산, 백두산의 산지초원에 자생하고, 중국 동북부, 우수리강에 분포한다. 비늘줄기는 흰색이고 육질이며 5∼6개의 비늘조각으로 되어 있다. 원줄기는 높이 25cm 내외이다. 잎은 마주나거나 3개씩 돌려나고 줄 모양이며, 윗부분에 달린 것은 끝이 안으로 말려서 덩굴손같이 보인다. 잎 끝은 날카롭고 잎자루가 없다.The family name is Fritillaria verticillata , and the Latin name is Fritillariae Bulbus, a perennial herbaceous plant belonging to the lily family. It is known that it plays an active role of ganghae, gangdam and hypotension. It grows in the mountainous prairies of Mt. Shimsan area in the northern part of Korea, Gapsan in South Hamgyong province, and Baekdusan mountain, and it is distributed in the northeastern part of China and the Yizhi River. The stem of the scales is white and fleshy and has 5 to 6 scales. The main stem is about 25cm high. Leaves are opposite, or alternate, with three lines, and the upper part is curled inward and looks like a tendril. The tip of the leaf is sharp and has no petiole.
진피는 귤(Citrus unshiu Markovich)과 병감(Citrus reticulata Blanco)의 과피를 말한다. 라틴명은 Citri Unshius Pericarpium이다. 맛은 쓰고 매우며, 성질은 따뜻하다. 비위가 허약하여 일어나는 구토, 메스꺼움, 소화불량 등에 쓰인다.The dandelion is citrus ( citrus unshiu Markovich ) and the disease ( Citrus reticulata Blanco ). The Latin name is Citri Unshius Pericarpium. The taste is very high, and the quality is warm. Nausea is caused by fragile vomiting, nausea, and indigestion.
황련(黃連)은 라틴명 Coptidis Rhizoma 인, Coptis japonica Makino 중국황련(中國黃連) Coptis chinensis Franchet, 삼각엽황련(三角葉黃連) Coptis deltoidea C. Y. Cheng et Hsiao 또는 운련(雲連) Coptis teeta Wallich (미나리아재비과 Ranunculaceae)의 뿌리줄기로서 뿌리를 제거한 것이다. 세균성 및 아메바성이질, 장염, 폐결핵, 백일해, 성홍열, 대엽성폐염, 급성결막염 등을 치료하는 데 효과가 있다. 중국 원산이며 생약용으로 한국·일본·중국 등지에서 재배하기도 한다. Copenhagen (黄连) is the Latin name Coptidis Rhizoma, Coptis japonica Makino Chinese Coptis (中國 黄连) Coptis chinensis Franchet, triangulated 黄连Coptis deltoidea CY Cheng et Hsiao or 雲 連Coptis The roots of teeta Wallich (Ranunculaceae) were removed. Bacterial and amoebic dysentery, enteritis, pulmonary tuberculosis, pertussis, scarlet fever, lobar pneumonia, acute conjunctivitis and so on. It is native to China and it is cultivated in Korea, Japan, China and so on for herbal medicine.
황금(黃芩)은 라틴명 Scutellariae Radix인, 속썩은풀 Scutellaria baicalensis Georgi (꿀풀과 Labiatae)의 뿌리로서 그대로 또는 주피를 제거한 것이다. 뿌리는 원뿔 모양이고 비틀어져 굽어 있으며, 바깥 면은 황갈색~진한 노란색이고, 질은 단단하면서 취약하고 절단하기 쉽다. 자른 면은 노란색이고, 중심부는 적갈색이다. 냄새가 거의 없고 맛은 약간 쓰다.The golden (黃 芩) is the Latin name Scutellariae Radix, The root of Scutellaria baicalensis Georgi (Lamiaceae and Labiatae) is either removed as it is or is removed. The roots are conical, twisted and curved, and the outer surface is tan to dark yellow. The vagina is firm, vulnerable and easy to cut. The cut surface is yellow and the center is reddish brown. There is little smell and taste is a little bit.
현삼(玄參)은 라틴명 Scrophulariae Radix 인, Scrophularia buergeriana Miquel 또는 중국현삼(中國玄參) Scrophularia ningpoensis Hemsley (현삼과 Scrophulariaceae)의 뿌리를 말한다. 설탕이 타는 것과 같은 특유한 냄새가 있고 맛은 약간 달며 후에 약간 쓰다. 해열제로 인후염 ·종기 ·림프선염에 사용할 수 있다고 보고되고 있다. 산지에서 자란다. The ginseng is the Latin name Scrophulariae Radix, Scrophularia buergeriana Miquel or Chinese ginseng Scrophularia ningpoensis refers to the roots of Hemsley ( hyacinth and Scrophulariaceae). There is a peculiar smell like sugar burning, a little taste and a little bit after. It is reported that it can be used as a fever reducing agent for sore throat, boils, and lymphatic arthritis. It grows in the mountains.
황백(黃栢)은 라틴명 Phellodendri Cortex인, 황벽나무 Phellodendron amurense Ruprecht 또는 황피수 (黃皮樹) Phellodendron chinense Schneider (운향과 Rutaceae)의 줄기껍질로서 주피를 제거한 것이다. 일반 알칼로이드가 지니는 전신작용을 하지 않기 때문에 다량으로 투여해도 부작용이 없으므로 정장제뿐 아니라 건위제로 사용할 수 있다. 또한, 이 약재에 대하여 여러 세균의 내성(耐性)도 생기지 않으므로 유행성 눈병이 유행할 때 세안 소독약으로도 사용할 수 있다. Hwanghaek is the Latin name Phellodendri Cortex, Phellodendron amurense Ruprecht or Phellodendron It is the stem skin of chinense Schneider (Rutaceae and Rutaceae), which removes the juniper. Since the general alkaloid does not have the systemic action, it can be used not only as a topical preparation but also as a side effect agent since it has no side effects even when administered in large amounts. In addition, since this bacterium does not cause resistance to various bacteria, it can be used as a cleansing disinfectant when epidemic eye disease is prevalent.
치자(梔子)는 라틴명 Gardeniae Fructus인, Gardenia jasminoides Ellis (꼭두서니과 Rubiaceae)의 잘 익은 열매로서 그대로 또는 끓는 물에 데치거나 찐 것이다. 「新編中葯志」에 의하면 치자나무 Gardenia jasminoides Ellis는 산치자(山梔子)라 하고, 우리나라 치자 Gardenia jasminoides Ellis var. grandiflora Nakai는 대치자(大梔子) 또는 수치자(水梔子)라 한다고 하였다. 그러나「한국식물명고」에 의하면 두 종은 동일한 종으로 보고 있다. 일본·대만·중국에 분포하며, 열매는 해열, 이담(利膽), 지혈 작용을 하는 것으로 알려져 있다. Gardenia is a ripe fruit of the Latin name Gardeniae Fructus, Gardenia jasminoides Ellis (madder and Rubiaceae), which is either bred or steamed in boiling water. Gardenia jasminoides Ellis is called "Gardenia" and Gardenia jasminoides Ellis var. The grandiflora Nakai is said to be Daisako or Suizuka. However, according to the Korean botanical name, both species are regarded as the same species. It is distributed in Japan, Taiwan and China. Fruit is known to have fever, ejaculation, and hemostasis.
창출(蒼朮)은 라틴명 Atractylodis Rhizoma인, 모창출(茅蒼朮) Atractylodes lancea de Candolle 또는 북창출(北蒼朮) Atractylodes chinensis Koidsumi (국화과 Compositae)의 뿌리줄기이다. 각지의 산에서 널리 자란다. 이뇨 작용, 조혈 자극 작용, 건위(健胃) 작용이 보고되어 있다. 맛은 쓰고 매우며 성질은 따뜻하다. Creation (蒼朮) is the Latin name Atractylodis Rhizoma, Atractylodes lancea de Candolle or north-arctic Atractylodes Chinensis Koidsumi (Chrysanthemum and Compositae) is the rootstock. It grows widely in mountains of various places. Diuretic action, hematopoietic stimulation action, and stomach action have been reported. The taste is very high and the quality is warm.
백출(白朮)은 라틴명 Atractylodis Rhizoma Alba인, 삽주 Atractylodes japonica Koidzumi ex Kitamura 또는 백출(白朮) Atractylodes macrocephala Koidzumi (국화과 Compositae)의 뿌리줄기로서 그대로 또는 주피를 제거한 것이다. 특이한 냄새가 있고 맛은 약간 쓰고 달며 씹으면 점성을 띠고 성질은 따듯하다. 전정작용, 마비 작용을 나타내며, 이뇨 작용 및 혈당 강하 작용, 항암 작용을 하는 것으로 보고되고 있다. Baekchul (白朮) is the Latin name of Atractylodis Rhizoma Alba, sapju Atractylodes japonica Koidzumi ex Kitamura or baekchul (白朮) Atractylodes macrocephala Koidzumi (Chrysanthemum and Compositae) as a root stem or junk is removed. It has a peculiar smell, taste a little bit weary, and if you chew it is viscous and its quality is warm. Vestibular action, diuretic action, hypoglycemic action, and has been reported to have anti-cancer action.
향부자(香附子)는 라틴명 Cyperi Rhizoma 이고, 학명은 Cyperus rotundus Linne (사초과 Cyperaceae)인 사초과에 속하는 다년생 초본식물이다. 뿌리줄기가 옆으로 길게 뻗으며 그 끝부분에 괴경이 생기고 수염뿌리가 내린다. 바닷가 모래땅이나 물가에 살며 제주도에서 나고, 세계의 열대 및 아열대에 분포한다. 통경·건위·진통·진경·행기(行氣)의 효능이 있다Hyangbuja is a Latin name Cyperi Rhizoma and its scientific name is Cyperus It is a perennial herbaceous plant belonging to the genus Rotundus Linne (Quercus and Cyperaceae). The rootstock stretches sideways, with a tuber at its end and a bearded root. They live in the sandy beaches or on the beaches of the sea, come out of Jejudo, and are distributed in the tropical and subtropical regions of the world. There is the efficacy of gyeonggyeonggwa,
생지황(生地黃)은 라틴명 Rehmanniae Radix Recens 이고, Rehmannia glutinosa Liboschitz ex Steudel (현삼과 Scrophulariaceae)의 신선한 뿌리로, 맛은 쓰고 약간 달며 성질은 몹시 차다. 응혈(凝血) 촉진 작용 · 강심(强心) 작용 · 이뇨 작용 · 혈당 강하 작용 · 혈압 상승 작용을 하는 것으로 알려져 있다. It is a fresh name of Rehmanniae Radix Recens and is a fresh root of Rehmannia glutinosa Liboschitz ex Steudel (ginseng and Scrophulariaceae). Its flavor is slightly worn and its quality is very cold. It is known that it acts to promote coagulation (coagulation), strong heart action, diuretic action, hypoglycemic action, and hypertension.
건지황(乾地黃)은 라틴명 Rehmanniae Radix Recens 이고, Rehmannia glutinosa Liboschitz ex Steudel (현삼과 Scrophulariaceae)의 건조한 뿌리로, 맛은 쓰고 약간 달며 성질은 몹시 차다. 자궁출혈, 월경 불순에 사용하는 것으로 보고되고 있다. It is the dry name of Rehmanniae Radix Recens, which is a dried root of Rehmannia glutinosa Liboschitz ex Steudel (Schengenia and Scrophulariaceae). Its taste is slightly worn and its quality is very cold. Uterine bleeding, and menstrual irregularities.
천궁(川芎)은 Cnidium officinale Makino, 중국천궁 (中國川芎) Ligusticum chuanxiong Hort. (산형과 Umbelliferae)의 뿌리줄기로서, 산형과에 속하는 다년생 초본식물. 중국산 식물로 우리나라에서 흔히 재배되며, 약성이 온화하고 맛이 시고, 진정효과 및 조혈효과가 있는 것으로 보고되고 있다. 생것 외에 물에 데쳐 복용하기도 한다. Chengdu (川芎) is a Cnidium officinale Makino, China Taipei (中國 川芎) Ligusticum chuanxiong Hort. (Hill and Umbelliferae), a perennial herbaceous plant belonging to the mountain type. It is a Chinese plant and it is commonly cultivated in Korea. It has been reported that it has mildness, tastiness, soothing effect and hematopoiesis. In addition to raw materials, it is often taken in water.
목향(木香)은 라틴명 Aucklandiae Radix 이고, 초롱꽃목 국화과의 여러해살이풀로, Aucklandia lappa Decaisne(국화과 Compositae)의 뿌리이다. 특유한 냄새가 있고 맛은 약간 쓰다. 발한·이뇨·거담 효과가 있으며, 유럽과 북아시아가 원산지이다. It is a Latin name Aucklandiae Radix, a perennial plant of Asteraceae, Aucklandia lappa is the roots of Decaisne (Compositae). There is a peculiar smell and the taste is slightly bitter. There are effects of sweating, diuretic and gossip, and Europe and northern Asia are the origin.
감초(甘草)는 라틴명 Glycyrrhizae Radix et Rhizoma, Licorice이고, Glycyrrhiza uralensis Fischer, 광과감초(光果甘草) Glycyrrhiza glabra Linne 또는 창과감초(脹果甘草) Glycyrrhiza inflata Batalin (콩과 Leguminosae)의 뿌리 및/또는 뿌리줄기로서 그대로 (즉, 껍질이 붙은 채로) 또는 주피를 제거한 것이다. 특이한 냄새가 나며 맛은 달다. 진해·거담, 근육이완, 이뇨작용을 한다. Licorice is the Latin name Glycyrrhizae Radix et Rhizoma, Licorice, Glycyrrhiza uralensis Fischer, Glycyrrhiza glabra Linne or licorice and licorice Glycyrrhiza inflata Batalin (leguminosae) roots and / or rootstock as it is (ie, with the bark attached) or removed from the juniper. It has a peculiar smell and taste is sweet. Jinhae, geomung, muscle relaxation, diuretic action.
생강(生薑)은 라틴명 Zingiberis Rhizoma Recens 이고, Zingiber officinale Roscoe (생강과 Zingiberaceae)의 생강목 생강과의 여러해살이풀로서, 동남아시아가 원산지이며, 뿌리줄기는 납작하게 눌려있거나 불규칙한 덩어리 모양이며 대개는 갈라졌거나 또는 갈라진 덩어리이다. 특유한 냄새가 나고 맛은 매우 맵다. 위액분비촉진, 소화력 증진, 심장흥분 작용, 혈액순환촉진, 억균작용이 보고되어 있다. The ginger is the Latin name Zingiberis Rhizoma Recens, Zingiber It is a perennial plant of officinale Roscoe (ginger and Zingiberaceae) with ginger tree ginger. Origin of Southeast Asia. Rootstock is a flattened or irregular lumpy shape, usually a split or cracked mass. The smell is distinctive and the taste is very spicy. Promoting gastric secretion, promoting digestive power, promoting cardiac stimulation, promoting blood circulation, and inhibiting activity.
빈랑(檳)은 라틴명 Areca Arecae Semen 이고, 종려목 야자나무과 교목으로, 말레이시아 원산이며, Areca catechu Linn (야자과 Palmae)의 잘 익은 씨로서 열매를 채취하여 물에 삶아 열매껍질을 벗긴 것이다. 종피는 외층과 내층으로 나누어진다. 외층은 여러 층의 가로로 배열한 납작한 석세포로 조성되어있고 그 안에는 갈색물질(tannin)이 들어있다. 석세포는 크기가 일정치 않으며 보통 세포간극을 볼 수 있다. 매 층은 갈색물질(tannin)이 들어있는 직사각형의 유세포로 조성되어있고 그 중에는 소수의 유관속이 흩어져 있으며 세포간극은 없다. 착입조직(錯入組織)은 종피 내층이 배유까지 뻗어 들어가서 형성된 것인데. 세포중의 대부분에는 갈색물질이 들어있다. 약간 특유한 냄새가 있으며 맛은 떫고 약간 쓰다. It is a Latin name Areca Arecae Semen, a palm-tree palm tree, native to Malaysia, ripe seeds of Areca catechu Linn (palm and Palmae), harvested and boiled in water. The seed coat is divided into an outer layer and an inner layer. The outer layer is composed of flat stone cells arranged horizontally in several layers and contains brown substance (tannin). Stone cells are not uniform in size and can usually be seen in cell spaces. Each layer is composed of rectangular flow cells containing tannin, with a small number of vascular channels scattered and no cell gap. The entrapped tissue is formed by the inner layer of the seed coat extending into the endosperm. Most of the cells contain brown substances. There is a slight peculiar odor, and the taste is slightly worn.
죽력(竹瀝)은 라틴명 Bambusae Succus 이고, 솜대 Phllylostachys nigra Munro var. henonis Stapf 또는 왕대 Phyllostachys bambusoides Sieb. et Zucc. (벼과 Gramineae)의 줄기에 열을 가할 때 유출되는 즙액이다. 맑은 황색 내지 황갈색이며 투명하다. 타는 냄새가 나고 맛은 담담하다. 알코올분해작용, 항균작용, 콜레스테롤강하작용이 보고되었다.The tabasheer is the Latin name Bambusae Succus, the scabbard Phllylostachys There is nigra Munro. henonis Stapf or throne Phyllostachys bambusoides Sieb. et Zucc. (Gramineae, Gramineae) is a juice that flows out when you apply heat to the stem. It is clear yellow to yellowish brown and transparent. I smell burning and the taste is cool. Alcohololytic, antibacterial, and cholesterol-lowering effects were reported.
본 발명자들은 상기 추출물의 모두가 피부에 유익한 생물학적 활성을 가지며, 상기 추출물 중 2이상의 복합 추출물, 바람직하게 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물의 복합 추출물, 가장 바람직하게, 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 생강 추출물, 빈랑 추출물 및 죽력 추출물의 복합 추출물은 시너지적 생물학적 활성을 가짐을 발견하였다. The present inventors have found that all of the above extracts have a biological activity beneficial to the skin, and that the extracts of two or more of the above extracts, preferably the extracts of mulberry, dermis, chrysanthemum, Extracts of mulberry leaves, extracts of mulberry leaves, extracts of mulberry leaves, extracts of golden mulberry leaves, extracts of mulberry leaves, extracts of yellow mulberry leaves, extracts of mulberry leaves, mulberry leaves, mulberry leaves, It was found that the combined extract of Gardenia extract, Creation extract, Lycoris spp., Herbal extract, Lycoris spp. Extract, Dried persimmon extract, Cucurbit extract, Mokchee extract, Licorice extract, Ginger extract, Anthelmintic extract and Capsicum extract had synergistic biological activity.
본 발명에 있어서, 용어 "추출물"은 상기 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농충액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.In the present invention, the term "extract" means an extract obtained by extracting the extract, a dilute or concentrated solution of the extract, a dried product obtained by drying the extract, a controlled preparation or a purified product of the extracted solution, Itself and extracts of all formulations which can be formed using extracts.
상기 추출물에는 각각의 식물을 설명하며 특정된 부위 외에도 그의 잎, 줄기, 나무껍질, 뿌리, 꽃 또는 꽃눈, 과실, 종자, 수액 및 전체 식물이 포함될 수 있다. Each of the above-mentioned extracts describes each plant and may include leaves, stems, bark, roots, flowers or flowers, fruit, seeds, sap, and whole plants in addition to the specified parts.
상기 추출물을 제조하기 위하여, 통상의 기술자는 당업계에 공지된 임의의 적합한 방법을 사용할 수 있다. 예를 들어, 용매 추출법에 의할 수 있다. 식물 전체 또는 임의의 부분을 분쇄한 다음(예를 들어, 블렌더), 추출 용매를 처리하여, 용매 추출물을 수득할 수 있다. 분쇄 전에 건조 과정(예를 들어, 40 내지 70℃에서 15 내지 50시간 동안의 건조)을 거친 다음 분쇄할 수도 있다. 또한, 용매 추출물은 감압 증류 및 동결건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. In order to prepare the above extract, one of ordinary skill in the art can use any suitable method known in the art. For example, a solvent extraction method can be used. The entire plant or any portion thereof may be ground (e.g., a blender) and then the extraction solvent may be treated to obtain a solvent extract. It may be subjected to a drying process (for example, drying at 40 to 70 DEG C for 15 to 50 hours) before pulverization and then pulverization. In addition, the solvent extract may be prepared in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying.
상기 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1 내지 C4의 저급 알코올; 글리세린, 부틸렌글라이콜, 프로필렌글라이콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게, 물, 저급알코올을 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있다. 상기 용매를 사용하여 1회 이상 추출하여 용매 추출물을 제조할 수 있으며, 상기 용매 추출물을 감압 증류한 후 동결건조 또는 분무 건조하여 얻은 건조 추출물을 제조할 수 있다. The kind of the extraction solvent used is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; And hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or mixtures thereof. Water and lower alcohols may be used alone or in combination of two or more. The solvent extract may be prepared by extracting the extract at least one time using the solvent, and the dry extract obtained by vacuum distillation or spray drying the solvent extract may be prepared.
상기 추출 용매의 양은 이용되는 추출 용매의 종류에 따라 다양할 수 있으나, 예를 들어 대상 식물의 건조 중량에 대하여 1 내지 20배, 또는 5 내지 20배로 사용할 수 있다. The amount of the extraction solvent may vary depending on the kind of the extraction solvent used, but may be, for example, 1 to 20 times, or 5 to 20 times the dry weight of the target plant.
이외에도, 당업계 공지된 다양한 추출 공정, 예를 들어, 온침(maceration), 인퓨전(infusion), 퍼콜레이션(percolation), 소화, 전즙(decoction), 고온 연속 추출(hot continuous extraction), 수성-알코올성 추출, 역류 추출, 마이크로파 보조 추출, 초음파 추출, 초임계 유체 추출, 조직편 추출(phytonic extract) (예를 들어, 하이드로-플루오로-카본 용매) 등) 등을 선택하여 사용할 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다.In addition, various extraction processes known in the art such as, for example, maceration, infusion, percolation, digestion, decoction, hot continuous extraction, aqueous- (For example, hydrofluoro-carbon solvent), etc.), which may be used alone or in combination with one another, may be used, for example, May be carried out by using two or more methods in combination.
[조성물][Composition]
본 발명에 따른 조성물은 패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물을 유효성분으로 포함한다. 더욱 바람직하게, 빈랑 추출물 및 죽력 추출물을 추가로 유효성분으로 포함할 수 있다. The composition according to the present invention can be used as an effective ingredient for the prevention and treatment of various diseases such as feverfew, dandruff extract, hwangryun extract, golden extract, ginseng extract, Huangbai extract, gardenia extract, , And ginger extract as active ingredients. More preferably, the bilberry extract and the bamboo extract may be further contained as an active ingredient.
본 발명에 있어서 "유효성분으로 포함된다"는 의미는 본 발명에 따른 조성물로부터 피부 개선 효과를 나타낼 수 있는 정도로, 추출물이 첨가되는 것을 의미하고, 피부 전달 및 안정화 등을 위하여 다양한 성분을 부성분으로 첨가하여 다양한 형태로 제형화(formulation) 가능함을 포함하는 의미이다.In the present invention, the term "included as an active ingredient" means that the extract is added to the skin composition of the present invention to such an extent that it can exhibit a skin improving effect, and various components are added as a sub ingredient And it is possible to formulate in various forms.
본 발명에 따른 조성물에 각각의 식물 추출물은 다음과 같은 비율로 포함될 수 있다. 예를 들어, 패모 추출물: 진피 추출물: 황련 추출물: 황금 추출물: 현삼 추출물: 황백 추출물: 치자 추출물: 창출 추출물: 백출 추출물: 향부자 추출물: 생지황 추출물: 건지황 추출물: 천궁 추출물: 목향 추출물: 감초 추출물: 생강 추출물의 중량비는 1: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10, 또는 1: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10, 또는 1: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5 또는 1: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3으로 포함될 수 있다. Each plant extract may be included in the composition according to the present invention in the following proportions. For example, the extracts of mulberry extracts: dermis extracts: Huangryu extract: golden extracts: ginseng extracts: yellowish white extracts: gardenia extracts: extracts extracts: 10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10, 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10, or 1: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3 can be included.
또한, 패모 추출물: 진피 추출물: 황련 추출물: 황금 추출물: 현삼 추출물: 황백 추출물: 치자 추출물: 창출 추출물: 백출 추출물: 향부자 추출물: 생지황 추출물: 건지황 추출물: 천궁 추출물: 목향 추출물: 감초 추출물: 생강 추출물: 빈랑 추출물: 죽력 추출물의 중량비는 1: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10: 0.01 ~ 10:0.01 ~ 10, 또는 1: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10, 또는 1: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5: 1 ~ 5:1 ~ 5 또는 1: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3: 1 ~ 3의 범위로 포함될 수 있다. Extract of Ganoderma lucidum: Extract of Ganoderma lucidum Extract: Extract of Ganoderma lucidum Extract: Extract of Ganoderma lucidum Extract: Extract of Ganoderma lucidum Extract: Ganoderma Extract: Ginger Extract: 10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.01-10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.01 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10: 0.1 to 10 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5 or 1: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: 1 to 3: Can.
본 발명에 따른 조성물은 이의 최종 형태 중에 적어도 약 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%, 0.0054%, 0.0055%, 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%, 0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650%, 0.0675%, 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000%, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%, 0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%, 0.5250%, 0.550%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% 또는 99% 이상의 범위로 본 발명의 1 이상의 추출물을 포함할 수 있다. The compositions according to the present invention may contain at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012% , 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026% %, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042% 0.005%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0058% , 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077% %, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095% 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275 %, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650% 0.0725%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000% , 0.2250, 0.2500, 0.2750, 0.3000, 0.3250, 0.3500, 0.3750, 0.4000, 0.4250, 0.4500, 0.4750, 0.5000, 0.5250, 0.550, 0.5750, 0.6000, 0.6250 %, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0% 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% , 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2% 5.4%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2% 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7% , 7.9%, 8. 9.2%, 9.4%, 9.4%, 9.5%, 9.6%, 8.3%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0% , 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21% %, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75% 85%, 90%, 95%, or 99% or more of the extract of the present invention.
또한, 본 발명에 따른 조성물에는 본 발명의 각각의 추출물이 조성물의 최종 형태 중에 적어도 약 0.0001% ~ 90%, 0.001% ~ 90%, 0.01% ~ 90%, 0.1% ~ 90%, 0.1% ~ 90%, 0.1% ~ 80%, 0.1% ~ 70%, 0.1% ~ 60%, 0.1% ~ 50%, 0.1% ~ 40%, 0.1% ~ 30%, 0.1% ~ 20% 또는 0.1% ~ 10%의 범위로 포함될 수 있다. The composition according to the present invention may also contain at least about 0.0001% to 90%, 0.001% to 90%, 0.01% to 90%, 0.1% to 90%, 0.1% to 90% %, 0.1 to 80%, 0.1 to 70%, 0.1 to 60%, 0.1 to 50%, 0.1 to 40%, 0.1 to 30%, 0.1 to 20% or 0.1 to 10% . ≪ / RTI >
상기 %는 조성물의 총 중량 대비 중량 또는 총 부피 대비 부피를 기준으로 계산할 수 있으며, 농도는 조성물의 목적하는 효과 또는 조성물이 혼입되는 제품에 따라 조정될 수 있다. The% can be calculated on the basis of the total weight of the composition or the volume relative to the total volume, and the concentration can be adjusted according to the desired effect of the composition or the product into which the composition is incorporated.
본 발명의 조성물은 모든 유형의 비히클 내로 제형화될 수 있다. 적합한 비히클의 예로는 에멀젼 (예를 들어, 수중유, 유중수, 수중실리콘, 실리콘중수, 수중유중수, 수중유, 유중수중유, 실리콘중수중유 등), 크림, 로션, 용액 (예컨대, 수성 및 하이드로-알코올 용액), 무수 베이스 (예를 들어, 립스틱 및 파우더), 젤, 연고, 페이스트, 밀크, 액체, 에어로졸, 고체 형태 또는 아이 젤리를 포함하나, 이에 제한되지 않는다. The compositions of the present invention may be formulated into any type of vehicle. Examples of suitable vehicles include, but are not limited to, emulsions (e.g., oil, water, water in silicone, water in silicone, water in heavy oil, water in oil, water in heavy water, But are not limited to, a hydro-alcoholic solution), a dry basis (e.g., lipstick and powder), a gel, ointment, paste, milk, liquid, aerosol, solid form or eye jelly.
또한, 본 발명의 조성물은 피부와 같은 표적 영역으로의 운반을 위해 캡슐화될 수도 있다. 캡슐화 기술은 예를 들어, 피부에 성분을 전달하는 운반 비히클로서 사용될 수 있는 리포좀, 소낭, 및/또는 나노입자 (예를 들어, 성분이 트랩핑(trap되고, 캡슐화되고/되거나 흡수되는 폴리머 물질을 포함하는 생분해성 및 비생분해성 콜로이드성 입자, 예를 들어 나노스피어(nanosphere) 및 나노캡슐을 포함)의 사용을 포함할 수 있으나, 이에 제한되지 않는다.The compositions of the present invention may also be encapsulated for delivery to a target area, such as the skin. Encapsulation techniques include, for example, the use of liposomes, follicles, and / or nanoparticles (e. G., Components that are trapped, encapsulated, and / or absorbed polymeric materials that can be used as a delivery vehicle But are not limited to, the use of biodegradable and non-biodegradable colloidal particles, including, for example, nanospheres and nanocapsules.
본 발명에 따른 조성물은 다양하게 제품화될 수 있다. 예를 들어, 화장료 조성물, 식품 조성물 등으로 제품화될 수 있다. The composition according to the present invention can be variously commercialized. For example, cosmetic compositions, food compositions, and the like.
상기 화장료 조성물은 예를 들어, 일반적인 유화 제형 및 가용화 제형의 형태로 제조된 것일 수 있다. 예를 들어, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이크림, 마사지 크림 등과 같은 크림, 에센스, 세럼, 화장연고, 스프레이, 오일젤, 젤, 팩, 선 스크린, 메이크업베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있으나, 이에 제한되지 않고 당업계 공지된 다양한 형태로 제형화될 수 있다. The cosmetic composition may be prepared, for example, in the form of a general emulsified formulation and a solubilized formulation. For example, creams, essences, serums, cosmetic ointments, sprays, oil gels, gels such as lotions such as lotion, facial lotion, body lotion and the like such as flexible lotion or nutrition lotion, nutrition cream, A lotion, a cleansing lotion, a makeup remover such as a cleansing oil, a cleansing foam, a soap, a body wash and the like such as a foundation, a pack, a sunscreen, a makeup base, a liquid type, a solid type or a spray type, But may be formulated into various forms known in the art without limitation.
상기 화장료 조성물에는 본 발명의 목적을 해하지 않는 이상, 본 발명에 따른 추출물 외에 당업계에서 화장료 조성물의 성분으로 공지된 통상의 성분을 임의로 선택하여 추가로 포함할 수 있다. 예를 들어, 방향제 (합성 및 천연), 염료 및 색 성분, 흡수제, 에멀젼화제, 안정화제, 윤활제, 용매, 보습제 (예: 연화제(emollient), 습윤제(humectant), 피막형성제, 폐색제(occlusive agent), 및 피부의 천연 보습 메커니즘에 영향을 주는 작용제(agent)를 포함함), 발수제(water-repellant), UV 흡수제 (물리적 및 화학적 흡수제, 예를 들어 파라아미노벤조산("PABA") 및 상응하는 PABA 유도체, 이산화티탄, 산화아연 등), 에센셜 오일(essential oil), 비타민 (예: A, B, C, D, E 및 K), 미량 금속 (예: 아연, 칼슘 및 셀레늄), 항-자극제(anti-irritant) (예: 스테로이드 및 비스테로이드성 항염증제), 항-미생물제(anti-microbial agent), 항산화제 (예: BHT 및 토코페롤), 킬레이트제 (예: 다이소듐 EDTA 및 테트라소듐 EDTA), 보존제 (예: 메틸파라벤 및 프로필파라벤), pH 조정제 (예: 수산화나트륨 및 시트르산), 흡수제(예를 들어, 알루미늄 전분 옥테닐석시네이트, 카올린, 옥수수 전분, 귀리 전분, 사이클로덱스트린, 탈크(talc), 및 제올라이트), 피부 블리칭(bleaching) 및 라이트닝(lightening) 작용제 (예를 들어, 하이드로퀴논 및 니아신아미드 락테이트), 습윤제 (예: 글리세린, 프로필렌 글리콜, 부틸렌 글리콜, 펜틸렌 글리콜, 소르비톨, 우레아 및 만니톨), 각질제거제(exfoliant) (예: 알파-하이드록시산 및 베타-하이드록시산, 예를 들어 락트산, 글리콜산 및 살리실산; 및 이들의 염), 발수제(waterproofing agent) (예: 마그네슘/알루미늄 하이드록시드 스테아레이트), 피부 컨디셔닝제(skin conditioning agent) (예: 알로에 추출물, 알란토인(allantoin), 비사볼롤(bisabolol), 세라마이드(ceramide), 다이메티콘, 히알루론산, 및 다이포타슘 글리시리제이트), 및 증점제(thickening agent) (예:조성물의 점도를 증가시킬 수 있는 물질, 예를 들어 카복실산 폴리머, 가교된 폴리아크릴레이트 폴리머, 폴리아크릴아미드 폴리머, 다당류 및 검(gum)) 및 실리콘 함유 화합물(예: 실리콘 오일 및 폴리오르가노실록산) 등이 포함될 수 있다. In addition to the extract according to the present invention, the above-mentioned cosmetic composition may further include optional ingredients commonly known as ingredients of the cosmetic composition in the art, so long as the object of the present invention is not impaired. Emulsifying agents, stabilizers, lubricants, solvents, moisturizers (e.g. emollients, humectants, film forming agents, occlusive agents, emulsifiers, water-repellant, a UV absorber (including physical and chemical absorbents such as para-aminobenzoic acid ("PABA") and corresponding (Eg, PABA derivatives, titanium dioxide, zinc oxide, etc.), essential oils, vitamins such as A, B, C, D, E and K, trace metals such as zinc, calcium and selenium, Antioxidants (such as BHT and tocopherol), chelating agents (such as disodium EDTA and tetrasodium EDTA), antioxidants (for example, antimicrobial agents) , Preservatives (such as methylparaben and propylparaben), pH adjusting agents (such as sodium hydroxide and citric acid) (E.g., aluminum starch octenyl succinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolites), skin bleaching and lightening agents (e.g., Hydroquinone and beta-hydroxynaphthoic acid (e.g., hydroquinone and niacinamide lactate), wetting agents such as glycerin, propylene glycol, butylene glycol, pentylene glycol, sorbitol, urea and mannitol, exfoliants (E.g., magnesium / aluminum hydroxide stearate), skin conditioning agents (e.g., aloe extracts), and the like, , Allantoin, bisabolol, ceramide, dimethicone, hyaluronic acid, and dipotassium glycyrrhizate), and thickening agents (e.g., (E.g., silicone oils and polyorganosiloxanes), and the like, which are capable of increasing viscosity, such as carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides and gums, .
상기 식품 조성물은 예를 들어, 음료, 강화수(fortified water), 에너지 드링크(energy drink), 영양 드링크(nutritional drink), 고형 식품, 비타민, 보조제(Supplement) 등) 등으로 제형화 될 수 있으나, 이에 제한되지 않는다. 상기 보조제에는 비타민, 무기질, 허브 또는 기타 식물, 아미노산, 효소 및 대사산물을 포함할 수 있다. 이러한 보조제는 경구 이용(oral consumption)에 적합하며, 경구로 투여될 수 있다.The food composition may be formulated into, for example, beverages, fortified water, energy drinks, nutritional drinks, solid foods, vitamins, supplements, etc., But is not limited thereto. Such adjuvants may include vitamins, minerals, herbs or other plants, amino acids, enzymes and metabolites. Such adjuvants are suitable for oral consumption and may be administered orally.
본 발명에 따른 조성물을 포함하는 키트로 제공될 수 있다. 본 발명에 따른 조성물은 용기에 포함되며, 용기는 병, 금속 튜브, 라미네이트 튜브, 플라스틱 튜브, 디스펜서, 압력 용기, 장벽 용기, 패키지, 컴파트먼트, 립스틱 용기, 컴팩트 용기, 화장용 조성물을 담을 수 있는 화장용 팬, 또는 다른 타입의 용기 예를 들어, 분산매체(dispersions) 또는 조성물 또는 유지되는 바람직한 병, 디스펜서, 또는 패키지 내로 주입 또는 블로우-몰드된 플라스틱 용기 등이 포함될 수 있으며, 이에 제한되지 않는다. 상기 키트에는 키트 또는 조성물을 사용하기 위한 지시서가 포함될 수 있으며, 지시서는 별개 용지에 기재될 수 있고, 또는 용기 표면, 용기 포장지의 표면 상에 기재될 수 있다. 지시사항은 글자, 어구, 약어, 그림 또는 기호 등이 포함되며, 이에 제한되지 않는다. 지시서에는 예를 들어, 키트 또는 조성물의 사용 방법, 적용 방법 및 유지 방법 등에 관한 지시사항이 포함될 수 있다. 용기에는 사전에 정해진 양에 따라 분배하여 담을 수 있다. May be provided as a kit comprising the composition according to the present invention. The composition according to the invention is contained in a container which can contain a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressure vessel, a barrier container, a package, a compartment, a lipstick container, a compact container, A cosmetic pan, or other type of container, including, but not limited to, a plastic container that is injected or blow-molded into a suitable bottle, dispenser, or package to be maintained or dispersed, . The kit may include an instruction for using the kit or composition, the instruction sheet may be described on a separate sheet, or may be described on the surface of the container surface, the surface of the container wrapper. Instructions include, but are not limited to, letters, phrases, abbreviations, pictures or symbols. The instructions may include, for example, instructions on how to use, apply and maintain the kit or composition. The container can be dispensed according to a predetermined amount.
본 발명에 따른 조성물은 국소용 피부 조성물로 제공될 수 있다. The composition according to the present invention may be provided as a topical skin composition.
또한, 본 발명에 따른 조성물을 피부에 국소 적용하는 방법을 제공할 수 있다. In addition, a method of topically applying the composition according to the present invention to the skin can be provided.
본 발명에 있어서, 용어 "국소 적용"은 조성물을 각질 조직의 표면상에 적용하거나 도포하는 것을 의미하고, "국소용 피부 조성물"은 각질 조직상에 국소 적용 또는 도포하기에 적합한 조성물을 포함한다. 이러한 조성물은 피부에 적용되는 경우 과도한 독성, 부적합성(incompatibility), 불안정성, 알러지 반응 등을 갖지 않는다는 점에서, 전형적으로 피부과학적으로 허용된다. 본 발명의 국소 피부 케어 조성물은, 피부에 적용된 후 현저한 적하(dripping) 또는 풀링(pooling)을 회피하기 위해, 선택된 점도를 지닐 수 있다.In the present invention, the term "topical application" means applying or applying the composition on the surface of keratinous tissue, and "topical skin composition" includes compositions suitable for topical application or application on keratinocytes. Such compositions are typically dermatologically acceptable in that they do not have excessive toxicity, incompatibility, instability, allergic response, etc. when applied to the skin. The topical skin care compositions of the present invention may have a selected viscosity to avoid significant dripping or pooling after application to the skin.
[피부 개선 효과][Skin improvement effect]
본 발명에 따른 조성물은 생물학적 활성을 가지며, 피부 개선에 우수한 효과를 발휘한다. The composition according to the present invention has biological activity and exerts excellent effects on skin improvement.
보다 구체적으로, 본 발명에 따른 조성물은 피부 미백 효과가 있다. More specifically, the composition according to the present invention has a skin whitening effect.
상기 피부 미백은 멜라닌 형성 과정을 억제 시켜 멜라닌 생성을 억제하는 것을 말한다. The skin whitening refers to inhibiting melanin formation and inhibiting melanin formation.
본 발명자들은 본 발명에 따른 복합 추출물을 멜라노마 세포에 처리하여 생성된 멜라닌의 양을 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 멜라닌 생성 억제 효과를 보임을 확인할 수 있었고, 피부 미백 효과가 공지되어 있는 알부틴에 상응하는 효과를 발휘함을 알 수 있었다. 본 발명에 따른 조성물은 멜라닌 생성 저해 효과가 뛰어나, 우수한 미백 효과를 나타냄을 확인하였다. As a result of measuring the amount of melanin produced by treating the melanoma cells according to the present invention, the inventors of the present invention confirmed that the melanin production inhibitory effect was enhanced compared with the case of treating each extract, It was found that the effect exerted an effect corresponding to known arbutin. It was confirmed that the composition according to the present invention was excellent in the effect of inhibiting melanin formation and exhibited excellent whitening effect.
또한, 본 발명에 따른 조성물은 주름 및 탄력 개선 효과가 있다. In addition, the composition according to the present invention has an effect of improving wrinkles and elasticity.
상기 피부 주름이란 피부가 쇠하여 생긴 잔줄을 의미하며, 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐과 엘라스틴의 감소, 외부환경 등에 의해 유발될 수 있다. The skin wrinkles are caused by the skin of the skin and can be caused by the cause of the gene, collagen and elastin present in the skin dermis, and the external environment.
상기 주름 개선은 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.The wrinkle improvement refers to suppressing or inhibiting the generation of wrinkles, or alleviating the already generated wrinkles.
상기 피부 탄력이란 진피층에 존재하는 엘라스틴(elastin)으로 구성된 탄력섬유 및 콜라겐(collagen)이라고 하는 교원섬유에 의해 나타나는 것으로, 상기 탄력 개선이란 탄력 감소를 억제 또는 저해하거나, 탄력을 유지 또는 향상시키는 것을 말한다.The skin elasticity refers to elastic fibers composed of elastin existing in the dermal layer and collagen fibers called collagen. The elasticity improvement refers to suppressing or inhibiting elasticity reduction or maintaining or improving elasticity .
본 발명자들은 본 발명에 따른 복합 추출물을 처리한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 콜라겐 합성 촉진 효과 및 엘라스타제 활성 저해 효과를 보임을 확인할 수 있었고, 피부 콜라겐 합성 촉진 효과가 공지되어 있는 비타민 C에 상응하는 효과를 보이며, 피부 엘라스타제 활성 저해 효과가 공지되어 있는 퀘세틴에 상응하는 효과를 발휘함을 알 수 있었다. 본 발명에 따른 조성물은 콜라겐 합성 촉진 효과 및 엘라스타제 활성 저해 효과가 뛰어나, 우수한 피부 주름 및 탄력 개선 효과를 나타냄을 확인하였다. As a result of treating the complex extract according to the present invention, the present inventors confirmed that they exhibited an enhanced collagen synthesis promoting effect and an elastase activity inhibiting effect, respectively, as compared with the case of treating each extract, And the effect of inhibiting the activity of skin elastase was shown to exert an effect corresponding to the known quercetin. The composition according to the present invention is excellent in collagen synthesis promoting effect and elastase activity inhibiting effect and shows excellent wrinkles and elasticity improving effect.
또한, 본 발명에 따른 조성물은 트러블 개선 효과가 있다. Further, the composition according to the present invention has an effect of improving the trouble.
상기 트러블은 피부자극 및 염증과 같은 증상을 말하며, 염증 반응에는 외부 자극에 의한 동통, 발열, 발적, 종창, 기능상실 등을 특징으로 하며, 조직학적으로는 소동맥, 모세혈관 및 소정맥의 투과성과 혈류증가를 동반한 확장, 혈장단백을 함유한 혈장의 삼출, 백혈구의 염증부위로의 이동 등을 포함한 복잡한 증상 등이 관찰되며, 피부자극 반응에는 홍반, 가려움, 발열 등을 특징으로 한다. The above-mentioned troubles are symptoms such as skin irritation and inflammation. The inflammatory reaction is characterized by pain, fever, redness, swelling and malfunction due to external stimuli. Histologically, the permeability of the arterioles, capillaries, , Complicated symptoms including enlargement accompanied by increase, excretion of plasma containing plasma protein, migration to inflammation site of leukocyte, and skin irritation reaction are characterized by erythema, itching, fever and the like.
상기 트러블 개선은 피부 자극 반응 및 염증 반응을 억제 또는 저해하거나, 이미 진행 중인 피부자극 반응 또는 염증 반응을 완화시키는 것을 말한다.The improvement of the trouble refers to inhibiting or inhibiting the skin irritation reaction and the inflammation reaction, or alleviating the skin irritation reaction or the inflammation reaction already in progress.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 NO 생성 저해 효과를 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 NO 생성 저해 효과를 보임을 확인할 수 있었고, NO 생성 저해 효과가 공지되어 있는 L-NMMA에 상응하는 효과를 발휘함을 알 수 있었다. 본 발명에 따른 조성물은 NO 생성 저해를 통해 우수한 피부 트러블 개선 효과를 나타냄을 확인하였다. As a result of measuring the inhibitory effect on NO production by treating the compound extract according to the present invention, the present inventors confirmed that the inhibitory effect on NO production was enhanced compared to the case of treating each extract, and NO inhibitory effect was known And exhibited an effect corresponding to that of L-NMMA. It was confirmed that the composition according to the present invention exhibits excellent skin trouble improving effect through inhibition of NO production.
또한, 본 발명에 따른 조성물은 항산화 효과가 있다. In addition, the composition according to the present invention has an antioxidative effect.
상기 항산화는 세포내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species;ROS)에 의한 세포의 산화를 억제하는 것을 말하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다. The antioxidant refers to inhibition of cellular oxidation by free radicals or reactive oxygen species (ROS), which are highly reactive according to oxidative stress caused by intracellular metabolism or ultraviolet rays, and free radicals Or removal of reactive oxygen species, thereby reducing damage to the cells.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 자유라디칼 소거능을 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 자유라디칼 소거능을 보임을 확인할 수 있었고, 자유라디칼 소거능이 공지되어 있는 비타민 C에 상응하는 효과를 발휘함을 알 수 있었다. 이로써, 본 발명에 따른 조성물은 우수한 항산화 효과를 나타냄을 확인하였다. As a result of measuring the free radical scavenging ability of the complex extract according to the present invention, the inventors of the present invention confirmed that they exhibited an increased free radical scavenging ability as compared with the case of treating each extract, and found that the free radical scavenging ability of vitamin C And the effect is comparable to that of the conventional method. Thus, it was confirmed that the composition according to the present invention exhibits an excellent antioxidative effect.
또한, 본 발명에 따른 조성물은 항당화 효과가 있다. In addition, the composition according to the present invention has an antiherating effect.
상기 당화는 과도한 당의 존재로 인해 생기는 당과 단백질이 결합해 단백질이 파괴되는 현상을 말한다. 당화가 진행되면 콜라겐과 엘라스틴에 영향을 미쳐 피부 탄력 저하외 각종 피부손상을 일으키게 된다. The glycation refers to a phenomenon in which a sugar and a protein are bound to each other due to the presence of excessive sugars and the protein is destroyed. As glycosylation progresses, it affects collagen and elastin, resulting in skin elasticity deterioration and other skin damage.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 항당화 효과를 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 항당화 효과를 보임을 확인할 수 있었고, 항당화 효과가 공지되어 있는 아미노구아니딘에 상응하는 효과를 발휘함을 알 수 있었다. 이로써, 본 발명에 따른 조성물은 우수한 항당화 효과를 나타냄을 확인하였다. As a result of measuring the antagonism effect by treating the complex extract according to the present invention, the inventors of the present invention have confirmed that they exhibit an elevated antihyperglycosylation effect as compared with the case of treating the respective extracts, and the aminoguanidine And the effect is comparable to that of the conventional method. Thus, it was confirmed that the composition according to the present invention exhibits excellent anticarcinogenic effect.
또한, 본 발명에 따른 조성물은 섬유아세포 증식 효과가 있다. In addition, the composition according to the present invention has a fibroblast proliferation effect.
본 발명에 따른 조성물 중에서도 '패모 추출물, 진피 추출물, 황련 추출물, 황금 추출물, 현삼 추출물, 황백 추출물, 치자 추출물, 창출 추출물, 백출 추출물, 향부자 추출물, 생지황 추출물, 건지황 추출물, 천궁 추출물, 목향 추출물, 감초 추출물, 및 생강 추출물'과 '빈랑 추출물 및 죽력 추출물'을 모두 포함하는 조성물에서 나타나는 효과이다. Among the compositions according to the present invention, the composition according to the present invention can be applied to a variety of compositions such as' mulberry extract, dermis extract, Huangyu extract, golden extract, ginseng extract, Huangyu extract, gardenia extract, Extracts, and ginger extracts', and 'bilberry extract and bamboo extract'.
본 발명에 따른 조성물은 in vitro 또는/및 in vivo에서 섬유아세포 증식에 사용될 수 있다. The composition according to the present invention may be used for fibroblast proliferation in vitro and / or in vivo.
본 발명자들은 본 발명에 따른 복합 추출물을 처리하여 세포증식율을 측정한 결과, 각각의 추출물을 처리하는 경우에 비해 상승된 세포증식효과를 보임을 확인할 수 있었고, 이로써 본 발명에 따른 조성물은 우수한 섬유아세포 증식 효과를 나타냄을 확인하였다. As a result of measuring the cell proliferation rate by treating the complex extract according to the present invention, the present inventors have confirmed that the extract according to the present invention exhibits an increased cell proliferation effect as compared with the case of treating each extract, Proliferative effect was confirmed.
이하, 본 발명을 구체적으로 설명하기 위해 실시예 및 실험예를 들어 상세하게 설명하기로 한다. 그러나 본 발명에 따른 실시예 및 실험예는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실시예 및 실험예에 한정되는 것으로 해석 되어서는 안 된다. 본 발명의 실시예 및 실험예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되는 것이다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples. However, the embodiments and experimental examples according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the above-described embodiments and experiments. The embodiments and experimental examples of the present invention are provided to enable those skilled in the art to more fully understand the present invention.
<실시예 1> 패모추출물의 제조≪ Example 1 >
패모를 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 패모추출물을 제조하였다.After drying thoroughly, the dried weight of 100 g was put into a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a peach extract.
<실시예 2> 진피추출물의 제조Example 2: Preparation of dermis extract
진피를 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 진피추출물을 제조하였다.The dermis was dried well, and then, 100 g of dry weight was placed in a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a dermis extract.
<실시예 3> 황련추출물의 제조Example 3: Preparation of Huangyan extract
황련을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 황련추출물을 제조하였다.The Rhizomes were well dried and cut into fine pieces. 100 g of dry weight was added to the flask, and the mixture was extracted by cooling with 1000 g of an extraction solvent (distilled water) for 3 days. The frozen extract was filtered through a filter having a pore size of 0.2 mu m to prepare a Rhodiola extract.
<실시예 4> 현삼추출물의 제조≪ Example 4 > Preparation of ginseng extract
현삼을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 현삼추출물을 제조하였다.The dried ginseng was thoroughly dried and finely divided. The dried weight of 100 g was placed in a flask, and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered through a filter having a pore size of 0.2 탆 to prepare an extract of ginseng.
<실시예 5> 황백추출물의 제조<Example 5> Preparation of yellowish white extract
황백을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 황백추출물을 제조하였다.The yellowish white was well dried and finely divided, and 100 g of dry weight was added to the flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a yellowish white extract.
<실시예 6> 황금추출물의 제조<Example 6> Preparation of gold extract
황금을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 황금추출물을 제조하였다.After the gold was dried well, the dried weight of 100 g was put into a flask and extracted with 1000 g of extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a golden extract.
<실시예 7> 치자추출물의 제조Example 7 Preparation of Gardenia Extract
치자를 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 치자추출물을 제조하였다.The grooming was well dried and cut into three pieces. 100 g of dry weight was put into a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a gardenia extract.
<실시예 8> 창출추출물의 제조<Example 8> Preparation of the resulting extract
창출을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 창출추출물을 제조하였다.The resulting mixture was thoroughly dried and finely divided. The dried weight of 100 g was placed in a flask, and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare an extract.
<실시예 9> 감초추출물의 제조Example 9 Preparation of licorice extract
감초를 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 감초추출물을 제조하였다.The licorice was dried well, and the dried weight of 100 g was put into a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a licorice extract.
<실시예 10> 백출추출물의 제조<Example 10> Preparation of dried extract
백출을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 백출추출물을 제조하였다.After thoroughly drying the flask, the flask was charged with 100 g of dry weight and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a crude extract.
<실시예 11> 향부자추출물의 제조Example 11: Preparation of herbal extracts
향부자를 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 향부자추출물을 제조하였다.The perfume was well dried and then placed in a flask. The flask was charged with 100 g of dry weight and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a herbal extract.
<실시예 12> 생지황추출물의 제조Example 12: Preparation of fresh persimmon extract
생지황을 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 생지황추출물을 제조하였다.After the fresh persimmon was cut three times, 100 g of the dry weight was put into a flask, and the mixture was extracted by cooling with 1000 g of an extraction solvent (distilled water) for 3 days. The frozen extract was filtered with a filter having a pore size of 0.2 탆 to prepare a raw persimmon extract.
<실시예 13> 건지황추출물의 제조Example 13: Preparation of dried persimmon extract
건지황을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 건지황추출물을 제조하였다.The dried persimmon was well dried and finely divided. The dried weight of 100 g was placed in a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a dried persimmon extract.
<실시예 14> 천궁추출물의 제조≪ Example 14 >
천궁을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 천궁추출물을 제조하였다.The celestial ghouls were well dried, and then placed in a flask with a dry weight of 100 g and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 탆 to prepare a cucumber extract.
<실시예 15> 목향추출물의 제조Example 15: Preparation of wood extracts
목향을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 목향추출물을 제조하였다.After thoroughly drying the slices, the dried weight of 100 g was put into a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a moss extract.
<실시예 16> 생강추출물의 제조Example 16: Preparation of ginger extract
생강을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 생강추출물을 제조하였다.The ginger was well dried and cut into three pieces. 100 g of dry weight was put into a flask, and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare ginger extract.
<실시예 17> 빈랑추출물의 제조<Example 17> Preparation of Bincho extract
빈랑을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 빈랑추출물을 제조하였다.After the slices were well dried, 100 g of the dry weight was placed in a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a crude extract.
<실시예 18> 죽력추출물의 제조<Example 18> Preparation of tabernacle extract
죽력을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 죽력추출물을 제조하였다.The tabasheasia was well dried, and after three folds, the dry weight of 100 g was put into a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 mu m to prepare a hydrolyzate extract.
<실시예 19> 패모, 진피, 황련, 황금, 현삼, 황백, 치자, 창출, 백출, 향부자, 생지황, 건지황, 천궁, 목향, 감초 및 생강 (16가지) 혼합추출물의 제조Example 19 Production of Mixed Extracts of Fenugreek, Dandelion, Rhododendron, Golden, Hyosung, Huangbai, Gardenia, Creation, Lycoris,
상술한 실시예와 같이 각각 추출물 형태로 제조한 패모, 진피, 황련, 황금, 현삼, 황백, 치자, 창출, 백출, 향부자, 생지황, 건지황, 천궁, 목향, 감초, 생강추출물을 동량 주입하여 패모, 진피, 황련, 황금, 현삼, 황백, 치자, 창출, 백출, 향부자, 생지황, 건지황, 천궁, 목향, 감초 및 생강 혼합추출물을 제조하였다.In the same manner as in the above-described examples, the same amount of extracts of the extracts of each of the extracts, dandelion, hwangryun, ginseng, hwangbong, gijia, Dipper, Rhododendron, Golden, Hyosung, Yellowish white, Gardenia, Creation, Lycoris, Rootstock, Rhizophora, Rhizopus, Rhizopus, Lycopersicum, Licorice and Ginger were prepared.
<실시예 20> 패모, 진피, 황련, 황금, 현삼, 황백, 치자, 창출, 백출, 향부자, 생지황, 건지황, 천궁, 목향, 감초, 생강, 빈랑 및 죽력 (18가지) 혼합추출물의 제조Example 20 Preparation of Mixed Extracts of Legumes, Dandelions, Rhododendrons, Golden, Hyosung, Huang Baek, Gijia, Creation, Lycoris,
상술한 실시예와 같이 각각 추출물 형태로 제조한 패모, 진피, 황련, 황금, 현삼, 황백, 치자, 창출, 백출, 향부자, 생지황, 건지황, 천궁, 목향, 감초, 생강, 빈랑, 죽력 추출물을 동량 주입하여 패모, 진피, 황련, 황금, 현삼, 황백, 치자, 창출, 백출, 향부자, 생지황, 건지황, 천궁, 목향, 감초, 생강, 빈랑 및 죽력 혼합추출물을 제조하였다.As in the above-mentioned examples, the extracts of the extracts of the respective species, such as fenugreek, dandelion, chrysanthemum, golden, hongshen, yellow, white, The extracts were mixed with water extracts, dandelion, chrysanthemum, golden, ginseng, yellowish white, gardenia,
<실험예 1> 항당화 효과 ≪ Experimental Example 1 >
항당화(anti-glycation) 효능을 확인하기 위하여, L-arginine과 포도당을 이용하여 당화 저해 활성을 측정하였다. In order to confirm anti-glycation efficacy, L-arginine and glucose were used to measure glycosylation-inhibiting activity.
먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌(arginine), 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 시료를 50ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충용액을 1대 4의 비율로 섞은 다음 96-웰 플레이트에 80 μl씩 분주하였다. 여기에 각각 50ppm으로 희석한 시료와 양성대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100 μl씩 첨가하였다. 이 시료들을 잘 섞어준 다음, 마지막으로 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70℃에서 4시간 동안 반응 시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420 nm에서 흡광도를 측정하여 당화 정도를 측정하였다. First, 1M L-arginine and 1M glucose were dissolved by using 1M phosphate buffer (pH 7.4), and prepared by diluting the sample to 50ppm with 1M phosphate buffer solution. 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1: 4, and then 80 [mu] l each was added to a 96-well plate. To each sample, 100 μl of 0.01 M aminoguanidine was added to each sample to be diluted to 50 ppm and used as a positive control. These samples were mixed well and finally glucose diluted with 1M phosphate buffer solution was added to the final concentration of glucose to 0.1 M and reacted at 70 ° C for 4 hours. The degree of saccharification was measured by measuring the absorbance of the 96-well plate at 420 nm using a spectrophotometer.
하기 식의 Glycation 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420 nm에서 흡광도를 측정하였다. 당화 저해 활성은 다음과 같은 식으로 구할 수 있다. Glycation group of the following formula was an experimental group in which 1M L-arginine and 1M glucose were added to induce glycation. Absorbance was measured at 420 nm by adding 1M L-arginine and sample alone without glucose to measure the absorbance of the sample itself. The saccharide inhibitory activity can be obtained by the following formula.
[수학식 1] [Equation 1]
(상기 수학식 1에서의 'Glycation 실험군'은 'Glycation 실험군의 흡광도'를 의미함.)('Glycation test group' in the above equation (1) means 'Absorbance of Glycation test group').
상기 표 1의 결과에서 나타난 바와 같이, 혼합추출물은 항당화 물질로 알려진 아미노구아니딘(aminoguanidin)과 비교할 때, 항당화 효과가 더욱 뛰어남을 알 수 있다. As shown in the results of Table 1 above, it can be seen that the mixed extract is superior to the aminoguanidine, which is known as an anticarious substance, in the anticarcinogenic effect.
<실험예 2> 멜라닌 생성 저해 효과 <Experimental Example 2> Effect of inhibiting melanin formation
멜라닌 생성 저해를 통한 미백 효과를 확인하기 위하여, Lotan R. 외(Cancer Res. 40:3345-3350, 1980)에 기재된 방법에 따라 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에, 추출물을 첨가하여 멜라닌 총량을 측정하였다. 실험 시, 먼저 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도에서 미백평가를 수행하였다. 음성 대조군으로는 DMSO를, 양성 대조군으로는 알부틴(albutin)을 사용하였다.In order to confirm the whitening effect through inhibition of melanin formation, a culture solution of B-16 mouse melanoma cells in rat was cultured according to the method described in Lotan R. et al. (Cancer Res. 40: 3345-3350, 1980) The total amount of melanin was measured by adding an extract. In the experiment, first the toxicity of melanoma cells in rats was evaluated and the whitening evaluation was carried out at a concentration that is not toxic. DMSO was used as a negative control group, and albutin was used as a positive control group.
구체적으로, 시료를 최종 농도가 100 ppm이 되도록 배지에 첨가하고, 알부틴은 100 ppm이 되도록 배지에 첨가한 후 멜라노마 세포를 3일간 배양하였다. 이후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심분리한 후, 멜라닌을 추출하였다. 떼어낸 세포는 수산화나트륨 용액(1N 농도) 1 ml를 가하여 10분간 끓여 멜라닌을 녹이고 분광 광도계를 이용하여, 400 nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다. Specifically, the sample was added to the medium to a final concentration of 100 ppm, arbutin was added to the medium to be 100 ppm, and melanoma cells were cultured for 3 days. Cells were then trypsinized, detached from the culture, centrifuged, and then melanin was extracted. The removed cells were incubated with 1 ml of sodium hydroxide solution (1N concentration), boiled for 10 minutes to dissolve melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.
상기 멜라닌 양은 단위 세포수당(1×106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 대조군에 대한 상대적인 멜라닌 총량을 저해율(%)로 계산하고 결과를 하기 표 2에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다.The amount of melanin was measured by an absorbance of 1 × 10 6 cells per unit cell, and the total amount of melanin relative to the control group was calculated as the inhibition rate (%). The results are shown in Table 2 below. As shown in FIG.
상기 표 2의 결과에서 볼 수 있듯이, 혼합추출물은 뛰어난 멜라닌 총량 감소 효과를 나타내어 미백 용도로 유용함을 알 수 있었다.As can be seen from the results of Table 2 above, the mixed extract showed excellent melanin total amount reduction effect and was found to be useful for whitening purposes.
<실험예 3> 항염 효과<Experimental Example 3> Anti-inflammatory effect
항염증 효과 및 피부트러블 개선 효과를 확인하기 위하여, RAW264.7 세포주 (ATCC number: CRL-2278)를 이용한 GRIESS 법으로 nitric oxide(NO) 생성 억제력 실험을 실시하였다.In order to confirm the anti-inflammatory effect and the improvement of skin trouble, nitric oxide (NO) production inhibition experiment was performed by GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 웰 하나에 3×105 개씩 들어가도록 24-웰 프레이트에 넣은 후, 24 시간 동안 배양하였다. 이어서, 최종농도 10ppm의 농도로 시료를 함유한 세포 배지로 교체하였다. 이때, NO-생성 억제물질인 L-NMMA(L-NG-Monomethylarginine)을 양성 대조군으로 함께 처리하여 30분 동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1 ㎍씩 처리하여 24시간 동안 배양하였다. 상층액을 100㎕씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100㎕씩 가해 상온에서 10분간 반응시키고, 540nm에서의 흡광도를 측정함으로써 NO 억제 효과를 판단하고, NO 생성 저해율(%)은 하기 수학식 2를 이용하여 계산하여 하기 표 3에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다.Specifically, RAW264.7 cells, macrophages of mice, were subcultured several times, placed in 24-well plates so as to enter 3x10 5 wells into each well, and cultured for 24 hours. Subsequently, the cell culture medium containing the sample was replaced with a final concentration of 10 ppm. At this time, L-NMMA (L-NG-Monomethylarginine), which is an inhibitor of NO production, was treated together as a positive control and cultured for 30 minutes. Lipopolysaccharide (LPS) 100 μl of the supernatant was transferred to a 96-well plate, 100 μl of GRIESS solution was added thereto, and the reaction was allowed to proceed at room temperature for 10 minutes. The absorbance at 540 nm was measured to determine the NO inhibitory effect. Calculated using Equation (2) and shown in Table 3 below. Experiments were performed three times each and expressed as average values.
[수학식 2]&Quot; (2) "
NO 생성 저해율(%)={(음성대조군의 흡광도 - 각 추출물의 흡광도)/음성 대조군의 흡광도} x 100 NO production inhibition rate (%) = {(absorbance of negative control - absorbance of each extract) / absorbance of negative control} x 100
상기 표 3의 결과에서 알 수 있듯이, 혼합추출물은 대표적인 항염 의약물질인 L-NMMA와 비교하였을 때, 상대적 활성은 다소 낮으나 천연물질로써 우수한 활성을 나타냄을 알 수 있었다. As can be seen from the results of Table 3, it was found that the mixed extracts exhibited excellent activity as a natural substance when compared with the representative anti-inflammatory drug L-NMMA, although the relative activity was somewhat low.
<실험예 4> 콜라겐 합성 촉진 효과 <Experimental Example 4> Promoting collagen synthesis
시료를 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 콜라겐 합성량을 측정하기 위해 시료를 최종 농도가 10 ppm이 되도록 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48 시간 배양한 후 배양액을 취하여 PICP EIA 키트로 각 농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다.The sample was added to the culture medium of human - derived fibroblasts to confirm the promoting effect of type I collagen synthesis at the cellular level. The synthesized collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit). In order to measure the amount of collagen synthesis, the sample was added to a fibroblast culture medium (DMEM medium) at a final concentration of 10 ppm and cultured for 48 hours. The culture broth was taken and the degree of type 1 collagen synthesis was measured at each concentration using a PICP EIA kit And measured at 450 nm using a spectrophotometer.
효과의 비교를 위하여 시료를 처리하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 ㎍/ml가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성 증가율은 음성 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 4에 나타내었으며, 실험은 4회씩 수행하여 평균값으로 나타내었다.For the comparison of the effects, the degree of collagen synthesis was measured in the same manner for the samples in which the culture medium of the untreated fibroblasts (negative control) and vitamin C (positive control) were added to a final concentration of 52.85 / / ml. The increase rate of collagen production was calculated by the ratio of relative collagen production to the negative control, and the results are shown in Table 4 below.
상기 표 4의 결과에서 볼 수 있듯이, 혼합추출물을 처리한 경우에 콜라겐 합성을 증가시켰고, 일반적으로 콜라겐 합성을 유도하는 것으로 잘 알려진 비타민C를 적용한 경우와 대응한 정도의 콜라겐 합성 효과를 나타내었다.As can be seen from the results in Table 4, the collagen synthesis was increased when the mixed extract was treated, and the collagen synthesis effect was comparable to that of vitamin C, which is generally known to induce collagen synthesis.
<실험예 5> 엘라스타제 활성 저해 효과 <Experimental Example 5> Elastase activity inhibitory effect
엘라스틴(Elastin)을 분해하는 효소인 엘라스테이즈(Elastase)의 활성 저해 효과를 다음과 같이 확인하였다.The activity inhibitory effect of Elastase, an enzyme that degrades elastin, was confirmed as follows.
엘라스테이즈(Elastase)는 사람의 백혈구 세포로부터 유래한 엘라스테이즈를 사용하였고, 엘라스테이즈의 기질로 합성 기질인 MeOSuc-Ala-Ala-Pro-Val-pNA를 사용하였다. 완충용액은 100mM의 Tris(pH 7.5) 용액을 사용하였다. 엘라스테이즈는 완충용액을 이용하여 최종적으로 0.2 mU을 사용하였다. 또한 엘라스테이즈의 합성 기질은 DMSO를 이용하여 100mM 용액을 만든 후 최종 농도가 0.5mM이 되도록 완충용액을 이용하여 희석하였다. 이 때, 양성 대조군은 엘라스테이즈 저해 물질로 알려진 쿼세틴(Quercetin)을 10ppm 농도로 넣은 것으로 설정하였다. 엘라스테이즈 저해 후보는 최종농도가 10ppm이 되도록 첨가하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 20분간 반응시켰다. 분광 광도계를 이용하여 1분 간격으로 405 nm에서 흡광도를 측정하여, 시간 대비 흡광도의 기울기를 구하여 효소의 활성도로 정하였다. 엘라스테이즈 저해율은 다음과 같이 계산하였다.Elastase used Elastase from human leukocyte cells and MeOSuc-Ala-Ala-Pro-Val-pNA as synthetic substrate for Elastase. The buffer solution used was 100 mM Tris (pH 7.5) solution. Finally, 0.2 mU was used for the ELASTASES using a buffer solution. In addition, the synthetic substrate of Elastase was diluted with buffer solution to make a final concentration of 0.5 mM by making a 100 mM solution using DMSO. At this time, the positive control group was set to contain 10 ppm of quercetin, which is known as an inhibitor of Elastinase. Ellazease inhibition candidates were added to give a final concentration of 10 ppm. The reaction was carried out in a 96-well plate and allowed to react at room temperature for 20 minutes. Absorbance was measured at 405 nm using a spectrophotometer at intervals of 1 minute, and the slope of the absorbance versus time was determined as the activity of the enzyme. Ella stasis inhibition rates were calculated as follows.
[수학식 3] &Quot; (3) "
엘라스타제 저해율은 상기 수학식 3을 이용해 계산하여 하기 표 5에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다.The inhibition rate of elastase was calculated using Equation (3) and shown in Table 5 below.
상기 표 5의 결과에서 볼 수 있듯이, 혼합추출물을 처리한 경우, 양성대조군 보다 상대적으로 효과가 다소 약하나, 우수한 엘라스타제 활성 저해 효과를 발휘함을 알 수 있었다. 따라서, 혼합추출물은 피부재생, 주름개선을 위한 용도로 사용할 수 있음을 알 수 있었다.As can be seen from the results in Table 5, when the mixed extract was treated, it was found that it exhibited a better inhibitory effect on elastase activity, though the effect was somewhat weaker than that of the positive control. Therefore, it was found that the mixed extract can be used for skin regeneration and wrinkle improvement.
<실험예 6> 항산화 효과 <Experimental Example 6> Antioxidative effect
혼합추출물에 대한 자유라디칼 소거능을 1,1-디페닐-2-피크릴히드라질(DPPH) 방법으로 측정하였다(Blois, Nature 181, 1190, 1958). DPPH는 비교적 안정한 자유라디칼로서 라디칼 상태로 존재 시 517㎚에서 최대 흡광을 보이며 라디칼이 소거되면 흡광성을 잃는다. DPPH는 시그마(Sigma)사의 것을 사용하였으며, 0.15 mM의 농도로 메틸 알코올에 녹여 사용하였다.The free radical scavenging ability of the mixed extract was measured by the 1,1-diphenyl-2-picryl hydrazyl (DPPH) method (Blois, Nature 181, 1190, 1958). DPPH is a relatively stable free radical, which shows maximum absorption at 517 nm in the presence of radicals and loses its absorbance when radicals are eliminated. DPPH was purchased from Sigma, and dissolved in methyl alcohol at a concentration of 0.15 mM.
먼저, 혼합추출물 또는 양성 대조군인 비타민 C를 96-웰 플레이트의 각각의 웰에 100μl씩 넣었다. 여기에 DPPH 용액을 100μl씩 첨가한 다음 상온에서 30분간 방치하고 마이크로플레이트 리더(BioTek EL-340)를 이용하여 517㎚에서의 흡광도를 측정하였다.First, 100 μl of mixed extract or vitamin C, a positive control, was added to each well of a 96-well plate. 100 μl of DPPH solution was added thereto, and the mixture was allowed to stand at room temperature for 30 minutes, and the absorbance at 517 nm was measured using a microplate reader (BioTek EL-340).
시료를 처리한 것의 흡광도가 대조군의 흡광도의 절반이 될 때의 추출물의 농도를 IC50으로 표시한 결과를 하기 표 6에 나타내었다. 본 실험은 3회 반복하였다. IC 50 represents the concentration of the extract when the absorbance of the sample is half the absorbance of the control group. The results are shown in Table 6 below. This experiment was repeated 3 times.
(비타민 C) Positive control group
(Vitamin C)
상기 표 6과 같이, 혼합추출물은 비타민 C와 비교할 때도 자유라디칼 소거능이 매우 강력하였으며, 이로써 항산화 효과가 우수함을 확인하였다. As shown in Table 6, the mixed extracts showed a strong free radical scavenging ability as compared with vitamin C, confirming that the antioxidative effect was excellent.
<실험예 7> 세포 증식 효과<Experimental Example 7> Cell proliferation effect
세포 증식 효과는 다음과 같은 방법으로 실험하였다. 사람의 섬유아세포(human fibroblast cell)를 96웰 플레이트(96 well plate, Corning사)에 접종하여 배양한 다음, 실시예 1 ~ 20를 1%의 농도로 2일간 적용하고, MTT 시험 방법을 수행하여 세포증식을 평가하였다. The cell proliferation effect was examined by the following method. Human fibroblast cells were inoculated into a 96-well plate (Corning) and incubated for 2 days at 1% concentration in Examples 1 to 20, followed by MTT assay Cell proliferation was evaluated.
보다 구체적으로, 인간 섬유아세포를 24well plate에 5×103 cells/well씩 동일하게 hemocytometer를 이용하여 계수한 후 분주하였다. 10% FBS를 함유하는 DMEM에서 48시간 배양하여 배양용기 표면적의 40 ~ 50%만큼 배양되면, 시료를 FBS-free DMEM으로 교체하여 24시간 더 배양하였다. 배양 후 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma M5655, USA) 용액 (2.5 mg/ml)을 50 ul 첨가하고 3시간 추가로 배양하였다. 그 후, 세포 배양액을 전부 버리고, 200 ul의 dimethyl sulfoxide (DMSO, Sigma D2650, USA)를 각 well 당 200ul씩 처리하여 교반한 후, 100 ul씩을 96 well로 취하여 Enzyme-Linked Immunosorbent Assay(ELISA)로 570nm에서 흡광도를 측정하였다. 대조군으로는 무혈청 배지를 사용하였으며, 비교군으로는 혈청(serum) 1%를 부가하여 사용하였다. 실험은 각각 3회씩 반복하였고, 그 결과를 표 7에 나타낸다. More specifically, human fibroblasts were counted by a hemocytometer in a 24-well plate at a density of 5 × 10 3 cells / well, and then divided. After culturing in DMEM containing 10% FBS for 48 hours and culturing for 40-50% of the culture vessel surface area, the sample was replaced with FBS-free DMEM and further cultured for 24 hours. After incubation, 50 μl of a solution of 2.5 mg / ml 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTT, Sigma M5655, USA) was added and cultured for additional 3 hours. Then, 200 μl of dimethyl sulfoxide (DMSO, Sigma D2650, USA) was added to each well and the mixture was treated with 200 μl of each solution. 100 μl of each well was taken in 96 wells and subjected to Enzyme-Linked Immunosorbent Assay (ELISA) Absorbance was measured at 570 nm. As a control group, serum-free medium was used, and 1% serum was added as a comparative group. The experiment was repeated three times each, and the results are shown in Table 7.
상기 표 7의 결과에서 보듯이, 본 발명에 따른 혼합 추출물은 세포증식을 통한 세포활성 효과가 우수하다 것을 알 수 있었다. 또한, 실시예 19의 혼합 추출물에 빈랑 및 죽령 추출물을 혼합한 실시예 20은 세포 증식 면에서 추가 상승 효과를 발휘함을 알 수 있었다. As shown in the results of Table 7, it was found that the mixed extract according to the present invention is excellent in cell activation effect through cell proliferation. It was also found that Example 20 in which the crude extract and bamboo extract were mixed with the mixed extract of Example 19 exhibited an additional synergistic effect in terms of cell proliferation.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160069102A KR20170136930A (en) | 2016-06-02 | 2016-06-02 | Composition for improving skin condition comprising herb extracts mixture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160069102A KR20170136930A (en) | 2016-06-02 | 2016-06-02 | Composition for improving skin condition comprising herb extracts mixture |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20170136930A true KR20170136930A (en) | 2017-12-12 |
Family
ID=60943751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160069102A KR20170136930A (en) | 2016-06-02 | 2016-06-02 | Composition for improving skin condition comprising herb extracts mixture |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20170136930A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200086868A (en) * | 2019-01-10 | 2020-07-20 | 주식회사 에스엠디솔루션 | Compositions for improving skin condition |
KR20220069504A (en) * | 2020-11-20 | 2022-05-27 | 주식회사 인투바이오 | Cosmetic composition containing Caesalpinia sappan L. extract, Phellodendron Amurense Bark extract, Gardenia Florida Fruit extract and Coptis chinensis extract complex |
KR20240062623A (en) * | 2022-11-02 | 2024-05-09 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
-
2016
- 2016-06-02 KR KR1020160069102A patent/KR20170136930A/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200086868A (en) * | 2019-01-10 | 2020-07-20 | 주식회사 에스엠디솔루션 | Compositions for improving skin condition |
KR20220069504A (en) * | 2020-11-20 | 2022-05-27 | 주식회사 인투바이오 | Cosmetic composition containing Caesalpinia sappan L. extract, Phellodendron Amurense Bark extract, Gardenia Florida Fruit extract and Coptis chinensis extract complex |
KR20240062623A (en) * | 2022-11-02 | 2024-05-09 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20170137544A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137552A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137564A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137553A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136378A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136930A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136919A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137412A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136911A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136912A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137549A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136389A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102585726B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137548A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136933A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137546A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136913A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137436A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102573376B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102585725B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102561150B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137550A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137542A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136922A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137556A (en) | Composition for improving skin condition comprising herb extracts mixture |